🏷

Classifications

IUIS Category

👪

Inheritance

1

X-linked recessive HP:0001419

TLR7 is on Xp22.2, so a single deleterious allele is sufficient in males and the disease presents in hemizygous men and boys. In the reported kindreds the allele is almost always maternally inherited from an unaffected heterozygous carrier mother; only one of ten tested index alleles was de novo. Female heterozygotes were not reported as having critical disease in the discovery cohorts, although a later large case-control study detected a TLR7 association signal in a female-only subgroup, which that study reads as evidence for a mechanism beyond simple X-linked recessive inheritance in males.

X-linked recessive inheritance

Show evidence (5 references)

PMID:35748970 SUPPORT REVIEW SYNTHESIS Other

"TLR7 deficiency TLR7 XL 301051"

The IUIS classification table row for this disorder, recording X-linked inheritance and the OMIM number (301051) that MONDO:0026767 maps to.

PMID:34413140 SUPPORT Human Clinical

"Based on the ten DNA samples available from the patients' mothers, only one of the TLR7 variants (L372M) was de novo in the index case."

Establishes maternal transmission as the rule rather than the exception, which is what makes carrier testing of mothers and pre-symptomatic testing of male relatives worthwhile.

PMID:38944683 SUPPORT INDIRECT Human Clinical

"Association signals for the X-chromosomal gene TLR7 were also detected in the female-only subgroup, suggesting the existence of additional mechanisms beyond X-linked recessive inheritance in males."

The caveat recorded in the description of this inheritance block: a female-only signal is not accounted for by hemizygosity, so the X-linked recessive label describes the male presentation rather than the whole genetic architecture.

+ 2 more references

◈

Mechanistic Hypotheses

1

Declining plasmacytoid dendritic cell numbers explain why penetrance rises with age

age_dependent_penetrance_pdc EMERGING

Evidence balance 3 support

Penetrance of TLR7 deficiency for severe or critical COVID-19 is high but incomplete, and the exceptions are mostly young. Among the hemizygous relatives identified by family screening, the three with asymptomatic, mild or moderate infection were aged 5, 5 and 38 years, while those with severe or critical pneumonia were older on average (mean 32.4 years against 16), though that group spans 7 to 71 years and includes children. The discovery study proposes that because blood pDC counts fall with age, a young TLR7-deficient boy still has enough pDC-independent or residual TLR9-driven interferon capacity to contain the virus, while the same genotype in an adult does not. A second, non-exclusive proposal from the same study is that genetic or epigenetic variation in TLR9 responses modifies the phenotype, since patient pDCs respond normally to TLR9 agonists. Which is right determines whether a hemizygous child identified by family screening should be counselled as being at risk now or as becoming at risk later.

Show evidence (3 references)

PMID:34413140 SUPPORT Human Clinical

"Of the 23 male patients carrying deleterious alleles of TLR7 infected with SARS-CoV-2, the 20 patients who developed severe (n=3) or critical (n=17) COVID-19 were aged 7-71 years (mean: 32.4 years) whereas the three patients who developed asymptomatic, mild, or moderate infection were younger:..."

The age contrast between penetrant and non-penetrant carriers that the hypothesis is built on.

PMID:34413140 SUPPORT REVIEW SYNTHESIS Other

"Blood pDC counts decrease with age (36–38), and this may contribute to the apparent increase in penetrance with age."

The proposed mechanism, stated by the authors as a possibility rather than a finding - which is why this is recorded as EMERGING. Graded OTHER with a REVIEW_SYNTHESIS quote role because the sentence cites prior pDC-ageing work rather than reporting a measurement made in this study.

PMID:35708626 SUPPORT Human Clinical

"The penetrance of AR IFNAR1 and IRF7 deficiencies for critical COVID-19 appears to be complete, whereas that of XR TLR7 deficiency is high, but incomplete, especially in young patients"

Independent statement of the age-skewed incomplete penetrance, contrasted against interferon-pathway defects whose penetrance is complete.

?

Discussions and Knowledge Gaps

3

Does B-cell-intrinsic TLR7 signalling contribute to the antibody response against SARS-CoV-2 in humans, as it does in mice, or is the human humoral response TLR7-independent?

HUMAN MODEL MISMATCH OPEN tlr7_b_cell_antibody_species_mismatch

Attached to

pathophysiology#Defective B Cell and Myeloid TLR7 Responsiveness

The two species give opposite answers, and both results are direct. In mice, Tlr7 deficiency abolishes germinal-centre-dependent class-switched IgG2b/IgG2c and neutralising antibody to SARS-CoV-2, and a B-cell-intrinsic requirement is demonstrated; a second murine study independently reports substantially reduced anti-SARS-CoV-2 antibody with delayed viral clearance. In TLR7-deficient humans given an mRNA vaccine, the RBD-specific memory B cell response is quantitatively and qualitatively similar to healthy donors and neutralising IgG is largely unaffected for seven months. The mismatch is mechanistically meaningful rather than a technical discrepancy: the human data are from a nucleoside-modified mRNA vaccine designed not to engage innate RNA sensors, whereas the murine data use inactivated virus and a pathogen-like particle carrying bacterial single-stranded RNA as a deliberate TLR7 ligand. So the comparison may be between two different antigens rather than between two species. It matters clinically: if the human B cell compartment does need TLR7 for a response to the virus itself, the normal mRNA-vaccine response does not license the conclusion that convalescent immunity in these patients is intact, and the entry's main intervention rests on that conclusion.

Proposed experiments

Natural-infection antibody response in TLR7-deficient patients versus relatives

tlr7_natural_infection_antibody_response

Measure RBD-specific class-switched IgG, memory B cell frequency and serum neutralising titre after natural SARS-CoV-2 infection (not vaccination) in TLR7-deficient patients, their non-carrier relatives and heterozygous mothers. Natural infection presents unmodified viral single-stranded RNA, which is the ligand the modified mRNA vaccine was engineered to avoid, so this is the comparison that separates a species difference from an antigen difference.

Would support

pathophysiology#Defective B Cell and Myeloid TLR7 Responsiveness

Would refute

pathophysiology#Defective B Cell and Myeloid TLR7 Responsiveness

Supporting outcome

Reduced class-switched RBD-specific IgG and neutralising titre in TLR7-deficient patients relative to infected non-carrier relatives, with preserved responses to mRNA vaccination in the same individuals.

Refuting outcome

Class-switched RBD-specific IgG, memory B cell frequency and neutralising titre after natural infection indistinguishable from infected non-carrier relatives, which would confine the B cell defect to the in vitro stimulation phenotype.

Show evidence (3 references)

PMID:37438976 SUPPORT Model Organism

"Upon repeated immunization with inactivated SARS-CoV2 or PLA COVID-19 vaccine, we show that Tlr7-deficiency abolished the germinal center (GC)-dependent production of RBD-specific class-switched IgG2b and IgG2c, and neutralizing antibodies to SARS-CoV2."

The murine side of the mismatch, including the B-cell-intrinsic requirement.

PMID:39289468 SUPPORT Model Organism

"Despite higher amounts of lung viral antigen, Tlr7 or Irf7 deficiency resulted in substantially reduced production of antibodies against SARS-CoV-2, thereby delaying the viral clearance."

Independent murine replication of the antibody defect, with the additional observation that it delays viral clearance.

PMID:36342455 REFUTE Human Clinical

"Sustained germinal center responses led to accumulation of somatic hypermutations in immunoglobulin heavy chain genes."

The human side: the germinal-centre step that fails in Tlr7-null mice proceeds in TLR7-deficient patients.

Does propofol sedation further suppress TLR7 signalling in a patient whose residual TLR7 function is already reduced, and should sedation choice differ in a TLR7-hypomorphic patient being ventilated for COVID-19?

INTERPRETATION OPEN tlr7_propofol_sedation_interaction

Attached to

pathophysiology#Abolished MyD88-Dependent Signal Transduction treatments#Early exogenous interferon therapy

Propofol binds TLR7 directly and hinders its association with MyD88, attenuating interferon induction in dendritic cells and in lung tissue. The pharmacological target is precisely this entry's signalling node, and the clinical setting in which these patients are identified is one in which propofol is routinely given: they are diagnosed while intubated for critical COVID-19 pneumonia. For an outright loss-of-function allele the question does not arise, since there is no signal left to inhibit. It arises for the hypomorphic and hypofunctional alleles, which retain measurable activity and account for several of the reported patients, and for heterozygous female carriers. This is recorded as an interpretation rather than as a treatment caution because the evidence is biochemical and murine: no study has measured interferon output in a TLR7-hypomorphic patient under propofol, and no clinical comparison against another sedative exists.

Show evidence (2 references)

PMID:35899460 SUPPORT In Vitro

"We also found that propofol directly bound to and hindered its association of TLR7 with MyD88."

The molecular interaction, at exactly the receptor-to-adaptor step this entry's pathophysiology node describes.

PMID:35899460 SUPPORT INDIRECT Model Organism

"R837 increased IFN-β expression in the lungs, and propofol attenuated IFN-β expression in an in vivo model of R837 intranasal instillation."

Shows the interaction reducing interferon output in lung tissue in vivo, which is the organ and the output that matter here. INDIRECT because it is a murine agonist-challenge model, not a patient.

Does TLR7 deficiency contribute to neurological deterioration after COVID-19, or is the single reported case a coincidence of two findings in one patient?

KNOWLEDGE GAP OPEN tlr7_neurological_sequelae

Attached to

phenotypes#Severe viral infection

One pediatric patient with post-COVID-19 neurological deterioration was found to carry a novel hemizygous frameshift TLR7 allele, and the reporting authors suggest TLR7 loss of function may contribute to neurological complications. That is a single case, the authors themselves hedge it, and no neurological phenotype appears in any of the cohort studies - so no neurological phenotype is curated in this entry. The gap is recorded rather than resolved because the cohorts were assembled on respiratory severity and would not have detected a neurological outcome had one existed. A second patient in whom TLR7 deficiency coexisted with ataxia-telangiectasia shows the shape of the confound: that patient's neurological signs were attributable to a homozygous ATM variant, with TLR7 accounting only for the COVID-19 severity.

Show evidence (2 references)

PMID:38093758 SUPPORT Human Clinical

"However, our preliminary findings also suggest TLR7 loss of function may contribute to neurological complications post-COVID-19, especially in young previously healthy patients."

The hypothesis, in the authors' own hedged terms, and the whole of the evidence for it.

PMID:34686943 SUPPORT Human Clinical

"We report a unique IEI patient with combined ATM and TLR7 deficiencies. The two genetic defects underlie A-T and critical COVID-19 in this patient, respectively."

The worked example of attributing neurological disease to the other gene and COVID-19 severity to TLR7 - the confound this gap is about.

⚙

Pathophysiology

9

TLR7 Loss of Function

Mechanism confidence: Established

Hemizygous TLR7 variants that abolish or substantially reduce receptor function. The reported spectrum is broad in kind and consistent in consequence: frameshift and nonsense alleles that remove the protein (p.Asn158Thrfs*11, p.Leu227fs) or truncate it (p.Lys684*, p.Phe670Leufs*8), the four-nucleotide deletion p.Gln710Argfs*18 of the original Dutch kindred, and missense alleles expressed at normal levels that are nonetheless dead in a signalling assay (p.Val795Phe, p.His781Leu, p.Leu988Ser, p.Asn215Ser). Grading is biochemical, not predictive: of 20 alleles found in one cohort of critical cases, 12 were loss-of-function, three hypomorphic and five neutral in an NF-kappaB reporter assay, so the functional test is what distinguishes a causal allele from a rare one.

TLR7 hgnc:15631

Genetic context variant_origin: GERMLINE zygosity: HEMIZYGOUS functional_impact_category: LOSS_OF_FUNCTION

TLR7 pattern recognition receptor activity GO:0038187 ⇓ LOSS OF FUNCTION

Downstream

Failure of Endosomal Single-Stranded RNA Sensing TLR7 is the receptor, so an allele that removes the protein or kills its signalling output removes the sensing step itself. The lesion is cell-intrinsic and reversible: re-expression of wild-type TLR7 in the patients' own cells restores the response, which is what establishes the variant as causal rather than correlated.

Show evidence (2 references)

PMID:32706371 SUPPORT Human Clinical

"Rapid clinical whole-exome sequencing of the patients and segregation in available family members identified loss-of-function variants of the X-chromosomal TLR7."

Identifies loss-of-function TLR7 alleles as the molecular lesion, from the study that first found the locus. The two specific genotypes named in this node's description (p.Gln710Argfs*18 and p.Val795Phe) are in the same abstract paragraph but are not quoted here, because the square brackets the source puts around the protein changes are stripped by the validator before matching.

PMID:34413140 SUPPORT In Vitro

"Twelve of the 20 alleles were loss-of-function (LOF) (including L988S in two patients, and M854I;L988S in another), three (p.L372M, p.I657T and p.P715S) were hypomorphic (activity < 25%), and the remaining five were neutral"

The allelic grading this node rests on, and the reason a rare TLR7 variant is not by itself a diagnosis.

Failure of Endosomal Single-Stranded RNA Sensing

Mechanism confidence: Established

TLR7 sits in the endosomal compartment and binds single-stranded RNA, including the SARS-CoV-2 genome delivered there by endocytosed virions. Without a functional receptor the ligand is not detected. The defect is specific to this receptor and not to endosomal sensing in general: the same patient pDCs respond normally to a TLR9 agonist, and no enrichment of deleterious variants was found at the adjacent X-linked gene TLR8.

detection of virus GO:0009597 ↓ DECREASED toll-like receptor 7 signaling pathway GO:0034154 ⇓ LOSS OF FUNCTION

single-stranded RNA binding GO:0003727 ↓ DECREASED

endosome GO:0005768

Downstream

Abolished MyD88-Dependent Signal Transduction Ligand binding is what recruits the MyD88 adaptor to the receptor's cytoplasmic TIR domain, so a receptor that does not engage its ligand never assembles the signalling complex. In silico modelling of the deleterious alleles reports the same thing from the protein side, with impaired binding of both viral RNA and MYD88.

Show evidence (2 references)

PMID:34413140 SUPPORT In Vitro

"pDCs from P8 and P14 did not produce type I IFNs (or IL-6) upon stimulation with a TLR7 agonist, whereas they responded to a TLR9 agonist"

The receptor-specific nature of the sensing failure: TLR7 agonist dead, TLR9 agonist intact, in the same cells.

PMID:34413140 SUPPORT INDIRECT Human Clinical

"We observed no significant enrichment for coding non-synonymous variants of the X-linked gene TLR8"

The negative control on the same chromosome, supporting the claim that the lesion is confined to TLR7 rather than to endosomal nucleic-acid sensing broadly.

Abolished MyD88-Dependent Signal Transduction

Mechanism confidence: Established

All TLR7 signalling runs through MyD88, and from there through IRAK4 to NF-kappaB and to the IRF7-dependent interferon arm. In TLR7-deficient cells this cascade is not engaged by TLR7 ligands. The reporter assay that grades the alleles reads NF-kappaB transcriptional activity, so the node is also the measurement the variant classification is built on; functionally, patient B cell lines fail to make TNF in response to TLR7 or TLR7/8 agonists.

MyD88-dependent toll-like receptor signaling pathway GO:0002755 ↓ DECREASED positive regulation of canonical NF-kappaB signal transduction GO:0043123 ↓ DECREASED

Downstream

Deficient Plasmacytoid Dendritic Cell Type I Interferon Production In pDCs the MyD88 complex is coupled to constitutively high IRF7, which is why TLR7 ligation in these cells produces type I interferon rather than only inflammatory cytokines. With the adaptor step never reached, interferon induction does not occur.

Impaired Type II Interferon Induction The same stimulation that fails to induce type I interferon also fails to induce IFN-gamma, so the signalling block costs both interferon arms rather than only the type I response. The link is indirect: IFN-gamma in a stimulated mixed leukocyte population is produced by T and NK cells responding to accessory cytokines from the TLR7-bearing cells, not by MyD88 signalling in the IFN-gamma-producing cell itself, so the intermediate step is known but was not measured separately in these patients.

Defective B Cell and Myeloid TLR7 Responsiveness TLR7 is expressed by B cells and by myeloid subsets as well as pDCs, and the adaptor block is the same in all of them, so the cellular phenotype extends beyond the interferon-producing compartment.

Show evidence (2 references)

PMID:34413140 SUPPORT In Vitro

"In response to agonists of TLR7 (imiquimod) or TLR7 plus TLR8 (R848), the EBV-B cell lines carrying these two mutations failed to produce TNF"

The functional readout of the abolished cascade in patient-derived cells, using an NF-kappaB-dependent output.

PMID:34952932 SUPPORT In Vitro

"Our investigation revealed a profound impairment of the TLR7 pathway in patients carrying loss-of-function variants."

Independent transcriptome-wide confirmation that the pathway, not merely one readout, is impaired in carriers of loss-of-function alleles.

Deficient Plasmacytoid Dendritic Cell Type I Interferon Production

Mechanism confidence: Established

The central node. pDCs are the body's dominant source of type I interferon on nucleic-acid sensing, producing 100 to 1,000 times more per cell than any other leukocyte subset after TLR7 stimulation, and they are the cell type in which TLR7 deficiency matters. Patient pDCs infected with SARS-CoV-2 induce the type I interferon gene module 10 to 100 times more weakly than control pDCs and fail to mature into the PD-L1-high S1 subset that produces most of the IFN-alpha. The defect is partial rather than absolute, which the discovery study attributes to TLR7-independent sensors, TLR9 among them. pDC numbers themselves are normal: deep immunophenotyping found no abnormality in the leukocyte subsets, so this is a functional and not a numerical defect. The module node this conforms to bundles interferon induction with downstream JAK-STAT signalling, and only the induction half is lost here: the interferon receptor and its JAK-STAT machinery are intact in TLR7 deficiency, which is what makes exogenous interferon a rational replacement rather than a futile one.

plasmacytoid dendritic cell CL:0000784

type I interferon production GO:0032606 ↓ DECREASED positive regulation of type I interferon production GO:0032481 ↓ DECREASED

Animal models

Tlr7-null mouse with immune-cell-restricted deficiency (bone marrow chimera) Mouse partially recapitulates Reproduces the interferon-production failure and, through the chimeras, locates it in the immune compartment - the compartment the human disease implicates.

Downstream

Unrestrained Early SARS-CoV-2 Replication in the Respiratory Tract Type I interferon is what restricts SARS-CoV-2 in the respiratory tract in the first days of infection. Without the pDC-derived burst the virus is not contained early, and the pDC compartment cannot be substituted for, because TLR7 is not expressed by lung or pulmonary epithelial cells and so the epithelial TLR3 arm of interferon immunity does not cover this lesion.

Show evidence (3 references)

PMID:34413140 SUPPORT In Vitro

"Induction of the 17 type I IFN genes in pDCs from TLR7-deficient patients was 10 to 100 times weaker than that in pDCs from healthy individuals"

The quantitative core of this node, measured in patient pDCs infected with SARS-CoV-2 itself rather than with a synthetic agonist.

PMID:34413140 SUPPORT In Vitro

"We confirmed that pDCs produced 100-1,000 times more type I IFN per cell than other leukocyte subsets upon TLR7 stimulation"

Establishes why the pDC is the cell that matters here, and why loss of its response is not covered by the other TLR7-expressing subsets.

PMID:34413140 SUPPORT In Vitro

"Deep immunophenotyping by CyTOF in seven patients with TLR7 deficiency revealed no major abnormalities in 18 peripheral blood leukocyte subsets, including pDCs, mDCs, monocytes, and B cells"

Supports the claim that this is a functional rather than a numerical defect, and is the reason a blood count does not screen for the condition.

Impaired Type II Interferon Induction

Mechanism confidence: Established

TLR7 stimulation of patient cells also fails to raise IFN-gamma. This arm is affected across the allelic spectrum rather than only in null alleles: a transcriptomic study of stimulated patient PBMCs found the failure of IFN-gamma upregulation even in cells carrying hypofunctional and hypomorphic variants that retain measurable NF-kappaB activity. It is recorded as a separate node because it is a distinct measured output of the same signalling block, and because it is what distinguishes TLR7 deficiency from a pure type I interferonopathy.

type II interferon production GO:0032609 ↓ DECREASED

Show evidence (2 references)

PMID:34952932 SUPPORT In Vitro

"Of note, a failure in IFNγ upregulation following stimulation was also observed in cells harboring the hypofunctional and hypomorphic variants."

The claim that this node makes beyond the type I arm: the type II defect extends to alleles that are not outright null.

PMID:34367187 SUPPORT In Vitro

"Functional testing of this variant revealed decreased type I and II interferon responses in peripheral mononuclear blood cells upon stimulation with the TLR7 agonist imiquimod, confirming a loss-of-function effect."

Independent replication in a separate kindred that both interferon arms are affected by a TLR7 missense allele.

Defective B Cell and Myeloid TLR7 Responsiveness

Mechanism confidence: Provisional

B cells and myeloid subsets (classical, intermediate and non-classical monocytes, myeloid dendritic cells) express TLR7 and are unresponsive to TLR7 ligands in these patients. What this costs clinically is not settled. In mice, B-cell-intrinsic Tlr7 signalling is required for germinal-centre-dependent class-switched neutralising antibody against SARS-CoV-2; in TLR7-deficient humans given a SARS-CoV-2 mRNA vaccine, the memory B cell and neutralising IgG response is essentially normal. The node is therefore recorded with the cellular defect established and the humoral consequence held open; see the HUMAN_MODEL_MISMATCH discussion.

B cell CL:0000236 classical monocyte CL:0000860 myeloid dendritic cell CL:0000782

toll-like receptor 7 signaling pathway GO:0034154 ⇓ LOSS OF FUNCTION

Show evidence (2 references)

PMID:34413140 SUPPORT In Vitro

"Human TLR7 is known to be expressed and functional only in leukocyte subsets: plasmacytoid and classical dendritic cells (pDCs and mDCs), monocytes (classical, intermediate, and non-classical), and B cells"

The expression pattern that defines which cells this node covers.

PMID:36342455 REFUTE Human Clinical

"The receptor-binding domain spike protein (RBD)-specific memory B cell response in all patients was quantitatively and qualitatively similar to healthy donors."

Refutes the stronger reading of this node - that the B cell defect translates into a defective humoral response in humans. Recorded here rather than omitted because it is the reason the node's confidence is PROVISIONAL.

Unrestrained Early SARS-CoV-2 Replication in the Respiratory Tract

Mechanism confidence: Provisional

With the interferon brake absent in the first days of infection, viral replication is not contained. This step is inferred in humans from the interferon defect and the clinical outcome rather than measured directly in patients' airways; the viral load measurement comes from TLR7-deficient mice, in which lung virus titres rise together with loss of lung type I and type III interferon and interferon-stimulated gene expression. The type III interferon loss is recorded on this node because the murine lung is where it was measured; no type III measurement exists in TLR7-deficient patients.

viral genome replication GO:0019079 ↑ INCREASED defense response to virus GO:0051607 ↓ DECREASED type III interferon production GO:0034343 ↓ DECREASED

Animal models

Tlr7-null mouse challenged with mouse-adapted SARS-CoV-2 Mouse recapitulates Reproduces the failure of viral control in the lung that the human disease infers from its interferon defect and clinical outcome.

Downstream

Severe viral infection The disease-defining susceptibility, expressed clinically as severe infection with one specific virus rather than broad viral susceptibility. The edge is drawn from the failure of viral containment rather than from the pneumonia node, which is one expression of that severe infection rather than its cause.

Hypoxemic COVID-19 Pneumonia Uncontrolled replication in the lower respiratory tract is what produces the pneumonia the patients present with. The clinical arm of this edge is the ascertainment itself: deleterious TLR7 alleles were enriched among men with critical COVID-19 pneumonia and absent from asymptomatically or mildly infected men of comparable age.

Lung Neutrophil Accumulation and Immunopathology A higher and more prolonged viral burden drives the inflammatory infiltrate that damages the lung. Demonstrated in TLR7-deficient mice, where the increased virus load is accompanied by neutrophil accumulation and worse lung pathology; the intermediate chemotactic steps are known but were not measured in patients.

Show evidence (2 references)

PMID:40162785 SUPPORT INDIRECT Model Organism

"We showed that TLR7 deficiency significantly increased lung virus loads and morbidity/mortality, which correlated with reduced levels of type I IFNs (Ifna/b), type III IFNs (Ifnl), and IFN-stimulated genes (ISGs) in the lungs."

The direct measurement of the viral-control failure that human studies infer, in a TLR7-null animal challenged with a mouse-adapted SARS-CoV-2.

PMID:39289468 SUPPORT INDIRECT Model Organism

"The deficiency of Tlr7 and Irf7 globally and/or in immune cells in mice increases the severity of COVID-19 via impaired IFN activation in both immune and/or non-immune cells, leading to increased lung viral loads."

Independent mouse replication linking the interferon defect to viral load and to severity, with bone-marrow chimeras locating the requirement in immune cells.

Lung Neutrophil Accumulation and Immunopathology

Mechanism confidence: Provisional

Neutrophil infiltration and inflammatory lung pathology in a lung in which the virus was never brought under control. The histology is murine: increased neutrophil accumulation and lung pathology in TLR7-null mice, with viral antigen in macrophages, pneumocytes and bronchial epithelial cells. No histological series from TLR7-deficient human lungs exists, so nothing more specific about the human lesion is asserted here. The sequence matters for how the disease is read: the inflammation here is downstream of a failed antiviral response, not of an excessive innate response, so TLR7-deficient patients are not interferonopathy patients and the mechanistic argument for immunosuppression as the primary intervention is weaker than in unselected severe COVID-19.

neutrophil CL:0000775 alveolar macrophage CL:0000583 pulmonary alveolar type 2 cell CL:0002063

neutrophil chemotaxis GO:0030593 ↑ INCREASED inflammatory response GO:0006954 ↑ INCREASED

Animal models

Tlr7-null mouse challenged with mouse-adapted SARS-CoV-2 Mouse recapitulates Reproduces the inflammatory lung lesion, and establishes its position downstream of the viral-control failure rather than as an independent process.

Downstream

Acute respiratory distress syndrome Alveolar injury with inflammatory infiltrate is the lesion underlying the hypoxaemic respiratory failure that defines critical disease in these patients.

Show evidence (1 reference)

PMID:40162785 SUPPORT INDIRECT Model Organism

"Moreover, immunohistochemical assessment of the lungs revealed increased numbers of SARS-CoV-2 antigen-positive macrophages, pneumocytes, and bronchial epithelial cells in TLR7-/- and IFNAR-deficient mice compared to control mice."

The cell types carrying viral antigen in the affected lung, which is why this node binds alveolar macrophage and type 2 pneumocyte alongside the neutrophil it is named for.

Hypoxemic COVID-19 Pneumonia

Mechanism confidence: Established

The clinical endpoint: pneumonia requiring oxygen, progressing in most reported patients to high-flow oxygen or mechanical ventilation. Across the discovery cohort the patients were aged 7 to 71 years with a mean of 34.4 years, markedly younger than the cohort they were drawn from, and two of sixteen died. Severity is graded rather than binary - the same allele produced critical pneumonia in one hemizygous relative, severe pneumonia in another, and asymptomatic infection in a third - which is the incomplete penetrance this entry records as a hypothesis rather than a settled quantity.

Downstream

Pneumonia Pneumonia is the organ manifestation in every reported symptomatic case; the cohorts were assembled on it.

Hypoxemia The pneumonia is hypoxaemic by definition of the cohorts: severe disease was defined by a low-flow oxygen requirement and critical disease by high-flow oxygen or ventilation.

Respiratory failure requiring assisted ventilation Progression to mechanical ventilation was the presentation in the index kindreds and is the usual course of the critical form.

Show evidence (1 reference)

PMID:34413140 SUPPORT Human Clinical

"The patients were aged 7 to 71 years and their mean age was lower than that of the total cohort (mean age of 34.4 years, versus 52.9 years for the total cohort, in which age ranged from 0.5 to 99 years). TLR7-deficient patients accounted for about 1.8% of the patients below the age of 60 years..."

The age distribution and outcome of the defined cohort, and the source of the age figures in this node's description.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

5

Immune 3

Severe viral infection HP:0031691

Show evidence (2 references)

PMID:34413140 SUPPORT Human Clinical

"None had previously been hospitalized for a severe viral illness, including influenza pneumonia. This cohort of patients thus suggests that TLR7 deficiency does not underlie severe disease caused by common viral infections other than SARS-CoV-2, or if so, with lower penetrance."

Supports the narrow reading recorded in this phenotype's description, and is the reason the HP binding is qualified in preferred_term rather than taken broadly.

PMID:35748970 SUPPORT REVIEW SYNTHESIS Other

"X-linked TLR7 deficiency represents a novel IEI predisposing to severe COVID-19."

The IUIS committee's own statement of the susceptibility, which is what places this disorder in the innate-immunity-defect category recorded above.

Pneumonia HP:0002090

Show evidence (1 reference)

PMID:33650967 SUPPORT Human Clinical

"Overall, we found TLR7 deleterious variants in 2.1% of severely affected males and in none of the asymptomatic participants."

Independent Italian replication of the enrichment of deleterious alleles in severe disease and their absence from asymptomatic infection.

Acute respiratory distress syndrome HP:0033677

Show evidence (2 references)

PMID:34367187 SUPPORT Human Clinical

"A CT-scan showed multiple diffuse ground-glass opacities and consolidations in all lung segments, meeting the criteria for ARDS."

Records the ARDS diagnosis itself, in a genetically confirmed patient and against the criteria the same paper cites (the Berlin definition).

PMID:34367187 SUPPORT Human Clinical

"Despite this therapeutic regiment, the patient's condition further deteriorated and he was referred to the Erasmus Medical Center for possible ECMO treatment."

Supports the severity statement in this phenotype's description rather than the diagnosis: progression to the degree of respiratory failure for which extracorporeal support is considered.

Respiratory 2

Hypoxemia HP:0012418

Show evidence (1 reference)

PMID:34413140 SUPPORT Human Clinical

"This study also included patients with severe COVID-19 pneumonia, defined as hospitalized patients with pneumonia that required low-flow oxygen (<6L/min); moderate COVID-19 pneumonia, defined as patients with pneumonia but did not require oxygen therapy"

The oxygen-requirement thresholds that the severity grading, and so this phenotype, rest on.

Respiratory failure requiring assisted ventilation HP:0004887

Show evidence (1 reference)

PMID:32706371 SUPPORT Human Clinical

"The mean duration of ventilatory support was 10 days (range, 9-11); the mean duration of ICU stay was 13 days (range, 10-16). One patient died."

Quantifies the ventilation requirement and outcome in the index patients, which is the basis for this phenotype and for its severity.

🧬

Genetic Associations

1

TLR7

Gene: TLR7 hgnc:15631 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (6 references)

PMID:34413140 SUPPORT Human Clinical

"TLR7 was the highest ranked of these genes (uncorrected P-value = 3.5×10−5) and the only gene that remained significant after correction for multiple testing"

The unbiased genome-level result that identifies TLR7 as the locus, rather than a candidate-gene assertion.

PMID:34413140 SUPPORT Human Clinical

"Each of these 24 deleterious variants had an individual MAF < 1.3x10-4 in men and their cumulative MAF in men was 6.5 x10-4"

The population allele frequency that makes a deleterious hemizygous variant in a young man with critical COVID-19 interpretable as causal.

PMID:40423910 SUPPORT Human Clinical

"The functional impact of rare TLR7 variants was assessed using a luciferase reporter assay and revealed that N215S is a loss-of-function (LOF) variant, while D332G exhibits an hypomorphic behavior."

Independent functional grading of further alleles, and the reason the loss-of-function/hypomorphic distinction is recorded as part of the genetic claim rather than assumed from the variant class.

+ 3 more references

💊

Medical Actions

3

SARS-CoV-2 mRNA vaccination

Action: Vaccination NCIT:C15346

Agent: mRNA COVID-19 vaccine NCIT:C181140

Platform: Vaccine

The one intervention with both a mechanistic rationale and direct supporting data in this disorder. Because TLR7 deficiency is clinically silent until infection, prophylaxis is what changes the outcome, and it was applied this way in practice: hemizygous relatives identified by family screening were fast-tracked for early vaccination. The rationale is not obvious a priori - TLR7 senses single-stranded RNA and an mRNA vaccine delivers it - so the key observation is that the humoral response to mRNA vaccination in TLR7-deficient patients is essentially normal in amplitude, duration and neutralising capacity, which the authors read as showing that induction of type I interferon is not required for an efficient humoral response to an mRNA vaccine. Whether the nucleoside-modified mRNA is sensed by endosomal TLRs at all is left open in their discussion, which notes that modified mRNA may still be partially recognised by those receptors, so the normal response is not explained here by assuming the vaccine bypasses TLR7.

Mechanism Target:

Unrestrained Early SARS-CoV-2 Replication in the Respiratory Tract — Vaccination does not repair the TLR7 lesion. It supplies adaptive immunity that acts in place of the missing innate interferon brake, so that the virus is met by pre-existing neutralising antibody rather than by an interferon response that cannot be mounted.

Show evidence (1 reference)

PMID:36342455 SUPPORT Human Clinical

"The amplitude and duration of, and viral neutralization by, RBD-specific IgG serological response were also largely unaffected by TLR7, IRF7, or IFNAR1 deficiencies up to 7 mo after vaccination in all patients."

Establishes that the protective arm vaccination relies on is intact in TLR7-deficient patients, which is what makes this a usable intervention rather than a hopeful one.

Show evidence (2 references)

PMID:34367187 SUPPORT Human Clinical

"Based on the TLR7 variant carriership, these individuals were fast-tracked for early vaccination."

Documents the intervention being applied on the basis of the genetic diagnosis in identified hemizygous relatives.

PMID:36342455 SUPPORT Human Clinical

"These results suggest that induction of type I IFN is not required for efficient generation of a humoral response against SARS-CoV-2 by mRNA vaccines."

The general form of the finding: the vaccine's mechanism does not run through the pathway that is broken in these patients.

Genetic counseling and pre-symptomatic testing of male relatives

Action: Genetic Counseling NCIT:C15240

Platform: Behavioral / lifestyle

The diagnosis in a proband makes the family actionable, which is unusual for a disease defined by an exposure. Mothers are typically heterozygous carriers and hemizygous male relatives can be identified before they are infected, which is what allows prophylaxis to be offered to the people who need it. Family screening in the discovery cohort identified 16 heterozygous women and seven hemizygous men beyond the index cases.

Show evidence (2 references)

PMID:34367187 SUPPORT Human Clinical

"A diagnosis of TLR7 deficiency could not only inform on treatment options for the patient, but also enables pre-symptomatic testing of at-risk male relatives with the possibility of instituting early preventive and therapeutic interventions."

States the purpose of cascade testing in this disorder.

PMID:34413140 SUPPORT Human Clinical

"Sanger sequencing of the TLR7 locus in the relatives of these patients identified the deleterious alleles in 16 heterozygous women from eleven families and seven hemizygous men from seven families"

The yield of cascade testing in the reported families, which is the quantitative case for doing it.

Early exogenous interferon therapy

Action: Pharmacotherapy NCIT:C15986

Agent: recombinant interferon beta NCIT:C495 pegylated interferon lambda-1a NCIT:C166435

Platform: Protein replacement

Mechanistically the obvious replacement: the lesion is a failure to produce type I interferon in a cell type whose receptor pathway is intact, so exogenous interferon bypasses the defect. It is a rational option rather than a demonstrated one - no trial or case series in TLR7-deficient patients supports it, and the argument is carried over from inborn errors of interferon signalling in general. Recorded here because the reasoning is explicit in the clinical literature on this disorder, and flagged as unproven because it is. The nearest randomised evidence comes from genotype-unselected COVID-19 trials of pegylated interferon lambda, a type III interferon, and its lesson is about timing rather than about this genotype. A single early subcutaneous dose in outpatients within seven days of symptom onset halved hospitalisation or emergency attendance, while two doses given to patients already admitted to hospital produced no benefit. If that time dependence carries over, it is awkward for this disorder specifically: TLR7-deficient patients are found because they are already critically ill, which is the window in which interferon did not work.

Mechanism Target:

Deficient Plasmacytoid Dendritic Cell Type I Interferon Production — Supplies the cytokine the patient's pDCs cannot make. The target is the production node rather than any downstream node because the receptor and JAK-STAT machinery are not affected by this lesion, so delivered interferon should still be sensed.

Show evidence (1 reference)

PMID:34367187 SUPPORT INDIRECT Human Clinical

"Although no data is yet available to support specific management of TLR7 deficiency or the at-risk hemizygous carriers, early hospitalization and IFN-based therapies in inborn errors of IFN signaling form rational treatment options"

The source states the rationale and, in the same sentence, that no supporting data exist - which is why this is graded INDIRECT and the treatment described as unproven.

Show evidence (4 references)

PMID:34367187 SUPPORT INDIRECT Human Clinical

"Strong host genetic factors that confer an increased risk to develop severe COVID-19 might serve as genomic biomarkers, along with other factors, that could be used for early diagnosis and preventative measures, and could allow the identification of possible molecular targets for treatment."

The general argument for genotype-directed therapy in this setting. Graded INDIRECT because it states a programme rather than a result in treated patients.

PMID:36780676 SUPPORT INDIRECT Human Clinical

"A total of 25 of 931 patients (2.7%) in the interferon group had a primary-outcome event, as compared with 57 of 1018 (5.6%) in the placebo group, a difference of 51% (relative risk, 0.49; 95% Bayesian credible interval, 0.30 to 0.76; posterior probability of superiority to placebo, >99.9%)."

The only randomised result showing that giving exogenous interferon early changes COVID-19 outcome. INDIRECT and double-qualified: the trial enrolled genotype-unselected outpatients, so it does not test this disorder, and the interferon was type III rather than type I.

PMID:36780676 SUPPORT INDIRECT Human Clinical

"Among patients with a high viral load at baseline, those who received pegylated interferon lambda had lower viral loads by day 7 than those who received placebo."

Shows the intervention acting on viral load, which is the step this treatment's target_mechanisms link asserts it acts on. Still INDIRECT for the reasons above.

+ 1 more reference

🌍

Environmental Factors

1

SARS-CoV-2 infection

Not a modifier of this disease but a constituent of it. The genotype produces no phenotype in its absence: the patients were previously well, had no history of severe viral illness, and in the index families COVID-19 segregated as an X-linked recessive trait conditioned on exposure to the virus. This is why the MONDO concept names the infection, and why the hemizygous relatives identified by screening were asymptomatic rather than undiagnosed.

Show evidence (1 reference)

PMID:34413140 SUPPORT Human Clinical

"The phenotypes of five hemizygous relatives of index cases infected with SARS-CoV-2 include asymptomatic or mild infection (n=2, 5 and 38 years), or moderate (n=1, 5 years), severe (n=1, 27 years), or critical (n=1, 29 years) pneumonia."

The exposure-conditioned phenotype distribution among carriers, which is what establishes infection as the trigger and shows the penetrance is incomplete.

Mechanism Target:

TRIGGERS Unrestrained Early SARS-CoV-2 Replication in the Respiratory Tract — The virus is the ligand the receptor cannot sense and the pathogen the interferon response cannot contain, so the exposure initiates the mechanism rather than aggravating a process already under way.

Show evidence (1 reference)

PMID:33650967 SUPPORT Human Clinical

"Recently, loss-of-function variants in TLR7 were identified in two families in which COVID-19 segregates like an X-linked recessive disorder environmentally conditioned by SARS-CoV-2."

States the gene-environment structure this link encodes: a Mendelian trait whose expression is conditional on the viral exposure.

🔬

Diagnosis

2

TLR7 sequencing in a young man with unexplained severe COVID-19

The diagnostic entry point. Because the genotype is clinically silent before infection, the disorder is found by sequencing TLR7 in a male patient whose severe COVID-19 is not explained by age or comorbidity, and the finding is then confirmed functionally.

Genetic Testing NCIT:C15709

Show evidence (1 reference)

PMID:34367187 SUPPORT Human Clinical

"This study supports a rationale for the genetic screening for TLR7 variants in young men with severe COVID-19 in the absence of other relevant risk factors."

The stated indication for testing, from the prospective screening study.

Functional confirmation of a candidate TLR7 allele

A rare TLR7 variant is not a diagnosis on its own: five of twenty alleles found in critical cases were neutral in a signalling assay, and four of eight previously published variants were likewise neutral. Confirmation is a signalling readout - an NF-kappaB reporter assay on the transfected allele, or loss of the TLR7-agonist response in the patient's own cells, with rescue by wild-type TLR7.

luciferase reporter signalling assay on the transfected TLR7 allele

No NCIT clinical-action term was bound for this assay. Searched the committed NCIT label cache with grep -i -E ",(Luciferase|Reporter Gene|Reporter Assay|Signal Transduction Assay)," cache/ncit/terms.csv, which returned nothing, and the OLS NCIT search for "Luciferase Reporter Assay", which returns substance and gene-product terms rather than a clinical intervention reachable from NCIT:C25218. The preferred_term is left free-text rather than bound to a broader procedure term that would lose the specificity.

Show evidence (2 references)

PMID:40423910 SUPPORT In Vitro

"The luciferase assay proves to be a reliable tool for evaluating TLR7 signaling, effectively distinguishing between neutral, LOF, and gain-of-function (GOF) variants."

Names the assay and states what it discriminates, which is the step that converts a rare variant into a diagnosis.

PMID:34413140 SUPPORT In Vitro

"Collectively, these findings suggest that 16 of the 21 patients in our cohort (Table 1), as well as only 6 of the previously reported 12 patients carry deleterious TLR7 variants."

Quantifies how much reclassification functional testing produces, including the halving of previously published diagnoses - the reason this step is listed separately.

📊

Prevalence

4

Male patients under 60 years with critical COVID-19 pneumonia, COVID Human Genetic Effort international cohort

Period Prevalence 1800.0 per 100,000 >1 in 1,000

Not a population prevalence. This is the proportion of a clinically defined group - unrelated male patients below 60 with unexplained critical COVID-19 pneumonia - who carry a biochemically deleterious hemizygous TLR7 allele (1.8%, 15 of the patients in that age band). It is the figure a clinician uses to decide whether to sequence TLR7 in such a patient, and it is conditional on the pandemic exposure.

Show evidence (1 reference)

PMID:34413140 SUPPORT Human Clinical

"Overall, by disrupting pDC-dependent type I IFN production, XR TLR7 deficiency accounts for at least 1% of cases of life-threatening COVID-19 pneumonia in men under 60."

The authors' own summary of the diagnostic yield in this clinical group.

Young (under 60) severe COVID-19 cases with no reported clinical risk factors, Spanish and Italian case-control series

Period Prevalence 2400.0 per 100,000 >1 in 1,000

2.4% of 378 young cases without clinical risk factors, against 0.24% of population-based controls. Replicates the discovery-cohort yield in an independent ascertainment and supplies the effect size (odds ratio 12.3, rising on incorporation of functional or structural evidence).

Show evidence (1 reference)

PMID:38944683 SUPPORT Human Clinical

"Rare deleterious TLR7 variants were present in 2.4% of young (<60 years) cases with no reported clinical risk factors (n = 378), compared to 0.24% of controls"

The case and control proportions this record reports.

Males in the general population (gnomAD v2.1), deleterious TLR7 alleles

Carrier Frequency 65.0 per 100,000 1–9 per 10,000 (carriers)

Cumulative minor allele frequency of the 24 biochemically deleterious TLR7 alleles in men, 6.5 per 10,000, equivalent to 65 per 100,000. Because TLR7 is X-linked and these are hemizygous states in males, the allele frequency is also the frequency of affected genotypes in men. The strictly loss-of-function subset (excluding hypomorphs) is about 2.2 per 10,000.

Show evidence (1 reference)

PMID:34413140 SUPPORT Human Clinical

"The cumulative allele frequency for deleterious TLR7 variants in the male general population is < 6.5x10-4"

The source of the 65 per 100,000 figure normalized in this record.

Children under 16 hospitalized for COVID-19 pneumonia, international cohort

Period Prevalence 6250.0 per 100,000 >1 in 1,000

Seven of 112 children (6.25%) hospitalized for COVID-19 pneumonia had X-linked recessive TLR7 deficiency, which made it the single commonest inborn error of type I interferon immunity in that paediatric series. Reported here because it is a different clinical group from the adult cohorts above, not because the disorder is commoner in children overall.

Show evidence (1 reference)

PMID:35708626 SUPPORT Human Clinical

"In an international cohort of 112 children (<16 yr old) hospitalized for COVID-19 pneumonia, we report 12 children (10.7%) aged 1.5-13 yr with critical (7 children), severe (3), and moderate (2) pneumonia and 4 of the 15 known clinically recessive and biochemically complete inborn errors of type..."

Gives both the denominator (112 children) and the count of TLR7-deficient children (7) from which the 6.25% in this record is taken.

🐁

Animal Models

2

Tlr7-null mouse challenged with mouse-adapted SARS-CoV-2

The model that supplies what human studies cannot: direct measurement of lung viral load, lung interferon output and lung histology under a controlled challenge. TLR7-null mice infected with mouse-adapted SARS-CoV-2 have higher lung virus titres, lower type I and III interferon and interferon-stimulated gene expression, more neutrophil infiltration, worse lung pathology and higher mortality than controls.

Species

Mouse

Genotype

Tlr7 knockout (TLR7-/-)

Publication

PMID:40162785

Pathograph links

Unrestrained Early SARS-CoV-2 Replication in the Respiratory Tract recapitulates fidelity: moderate observes: tissue Reproduces the failure of viral control in the lung that the human disease infers from its interferon defect and clinical outcome.

Limitations: The challenge is a mouse-adapted virus, not the human pathogen, and the mouse lesion is a whole-animal knockout rather than one of the graded human alleles. More importantly the cellular geography differs: human TLR7 deficiency acts through pDC-derived interferon with no epithelial contribution, since human lung epithelium does not express TLR7, whereas the mouse study reports reduced interferon-stimulated gene expression in the lung and viral antigen in bronchial epithelial cells.

Readouts

Lung virus load

Direction: INCREASED

Interpretation: The quantitative correlate of failed viral containment, which is the step the human pathograph asserts without measuring.

Show evidence (1 reference)

PMID:40162785 SUPPORT Model Organism

"We showed that TLR7 deficiency significantly increased lung virus loads and morbidity/mortality"

Reports the measurement and its direction.

Lung Neutrophil Accumulation and Immunopathology recapitulates fidelity: moderate observes: tissue Reproduces the inflammatory lung lesion, and establishes its position downstream of the viral-control failure rather than as an independent process.

Limitations: Mouse neutrophil biology and the mouse-adapted virus both differ from the human disease, and no histological series from TLR7-deficient human lungs exists to compare against.

Readouts

Lung neutrophil accumulation and histopathology

Direction: INCREASED

Interpretation: The structural correlate of the immunopathology node in this model.

Show evidence (1 reference)

PMID:40162785 SUPPORT Model Organism

"A detailed evaluation of MA-CoV-2-infected lungs revealed increased neutrophil accumulation and lung pathology in TLR7-/- mice."

Reports the histological measurement behind this readout.

Show evidence (1 reference)

PMID:40162785 SUPPORT Model Organism

"Additionally, given the similar disease outcomes in control, TLR7-/-, and IFNAR-deficient MA-CoV-2-infected mice and coronavirus disease 2019 (COVID-19) patients, we propose that MA-CoV-2-infected mice constitute an excellent model for studying COVID-19."

The authors' own claim for the model's relevance. Cited as the basis for treating it as informative, not as independent validation of that claim.

Tlr7-null mouse with immune-cell-restricted deficiency (bone marrow chimera)

Addresses which compartment the requirement sits in. Global and immune-cell-restricted Tlr7 or Irf7 deficiency both worsen murine COVID-19 through impaired interferon activation and higher lung viral load, and both also reduce anti-SARS-CoV-2 antibody production, delaying viral clearance.

Species

Mouse

Genotype

Tlr7 knockout and Irf7 knockout, including bone marrow transplant chimeras

Publication

PMID:39289468

Pathograph links

Deficient Plasmacytoid Dendritic Cell Type I Interferon Production partially recapitulates fidelity: moderate observes: cellular Reproduces the interferon-production failure and, through the chimeras, locates it in the immune compartment - the compartment the human disease implicates.

Limitations: The model does not isolate pDCs, which is the specific cell the human disorder turns on; it reports the immune compartment as a whole and additionally implicates non-immune cells, which the human lesion cannot involve because human lung epithelium does not express TLR7. The study also pairs Tlr7 with Irf7, a gene acting downstream of several sensors, so not every reported effect is attributable to TLR7.

Readouts

Circulating interferon alpha and gamma

Direction: DECREASED

Interpretation: Systemic consequence of the production defect, measured in the circulation rather than in sorted cells.

Show evidence (1 reference)

PMID:39289468 SUPPORT Model Organism

"These effects are associated with reduced IFN alpha and gamma levels in the circulation."

Reports the measured direction of both interferon arms in the model.

Show evidence (1 reference)

PMID:39289468 SUPPORT Model Organism

"We demonstrate that at the early phase of infection, SARS-CoV-2 causes the upregulation of Tlr7, Irf7, and IFN pathways in the lungs of the infected mice."

Establishes that the pathway is engaged early in infection in this model, which is the premise for using its knockout as a model of the human timing.

{ }

Source YAML

click to show

name: Immunodeficiency 74, COVID-19-Related, X-Linked
creation_date: "2026-10-01T20:11:01Z"
category: Mendelian
disease_term:
  preferred_term: X-linked recessive TLR7 deficiency
  term:
    id: MONDO:0026767
    label: immunodeficiency 74, COVID-19-related, X-linked
synonyms:
- immunodeficiency 74, COVID19-related, X-linked, X-linked recessive
- IMD74
- TLR7 deficiency
- X-linked recessive TLR7 deficiency
- XR TLR7 deficiency
description: >-
  Immunodeficiency 74 is X-linked recessive TLR7 deficiency: an inborn error of
  innate immunity in which hemizygous loss-of-function or hypomorphic variants of
  the X-chromosomal gene TLR7 abolish endosomal sensing of viral single-stranded
  RNA, and whose only consistently reported clinical consequence is
  severe-to-critical COVID-19 pneumonia in males. TLR7 is the single-stranded-RNA
  receptor whose ligation in plasmacytoid dendritic cells (pDCs) drives the
  largest burst of type I interferon any human leukocyte produces. In TLR7-deficient
  men that burst does not happen: patient pDCs exposed to SARS-CoV-2, or to
  TLR7-specific agonists, fail to induce type I interferon genes and fail to mature,
  while their response to a TLR9 agonist is intact, which localises the defect to
  the receptor rather than to the cell.

  The disease is unusual among inborn errors of immunity in how narrow it is. TLR7
  is not expressed in lung or pulmonary epithelial cells, so the lesion does not
  impair the TLR3-dependent epithelial arm of interferon immunity that other
  interferon-pathway defects hit; and the patients, who were ascertained through
  critical COVID-19, had not previously been hospitalised for any severe viral
  illness, influenza pneumonia included. It is also an inborn error that is defined
  by an exposure: the genotype is clinically silent until SARS-CoV-2 arrives, so
  COVID-19 segregates in these families as an X-linked recessive trait conditioned
  on infection. Penetrance for severe or critical disease is high but incomplete,
  and appears lower in young children, for whom the circulating pDC compartment is
  larger.

  It is quantitatively important rather than merely instructive. In the COVID Human
  Genetic Effort cohort, biochemically deleterious TLR7 variants accounted for about
  1.8% of unrelated male patients with critical COVID-19 pneumonia below 60 years of
  age, and were absent from asymptomatically or mildly infected men. Independent
  Italian and Spanish/Italian series found deleterious variants in 2.1% and 2.4% of
  comparable severe cases. Because the cumulative frequency of deleterious TLR7
  alleles in men in the general population is below 6.5 per 10,000, a deleterious
  hemizygous variant found in a previously healthy young man with critical COVID-19
  is a diagnosis rather than an incidental finding, and it makes his male relatives
  testable before they are infected.
parents:
- inborn error of immunity
- X-linked recessive disease
references:
- reference: PMID:34413140
  title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
- reference: PMID:32706371
  title: Presence of Genetic Variants Among Young Men With Severe COVID-19.
- reference: PMID:35748970
  title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
classifications:
  iuis_category:
    classification_value: innate immunity defect
    notes: >-
      IUIS 2022 phenotypic classification (Tangye et al., PMID:35748970). TLR7
      deficiency is listed in that update's Table 6 of defects in intrinsic and
      innate immunity, in the group of innate defects conferring predisposition to
      viral infection, with mode of inheritance XL and OMIM 301051 - the same OMIM
      number MONDO:0026767 carries as an exact match. The update's text calls
      X-linked TLR7 deficiency a novel IEI predisposing to severe COVID-19.
inheritance:
- name: X-linked recessive
  description: >-
    TLR7 is on Xp22.2, so a single deleterious allele is sufficient in males and the
    disease presents in hemizygous men and boys. In the reported kindreds the allele
    is almost always maternally inherited from an unaffected heterozygous carrier
    mother; only one of ten tested index alleles was de novo. Female heterozygotes
    were not reported as having critical disease in the discovery cohorts, although a
    later large case-control study detected a TLR7 association signal in a female-only
    subgroup, which that study reads as evidence for a mechanism beyond simple
    X-linked recessive inheritance in males.
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  evidence:
  - reference: PMID:35748970
    reference_title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "TLR7 deficiency TLR7 XL 301051"
    explanation: >-
      The IUIS classification table row for this disorder, recording X-linked
      inheritance and the OMIM number (301051) that MONDO:0026767 maps to.
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Based on the ten DNA samples available from the patients' mothers, only one of the TLR7 variants (L372M) was de novo in the index case."
    explanation: >-
      Establishes maternal transmission as the rule rather than the exception, which
      is what makes carrier testing of mothers and pre-symptomatic testing of male
      relatives worthwhile.
  - reference: PMID:38944683
    reference_title: Stratified analyses refine association between TLR7 rare variants and severe COVID-19.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Association signals for the X-chromosomal gene TLR7 were also detected in the female-only subgroup, suggesting the existence of additional mechanisms beyond X-linked recessive inheritance in males."
    explanation: >-
      The caveat recorded in the description of this inheritance block: a female-only
      signal is not accounted for by hemizygosity, so the X-linked recessive label
      describes the male presentation rather than the whole genetic architecture.
  - reference: PMID:36327219
    reference_title: "Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "This association was consistent across sexes."
    explanation: >-
      The same point from the burden side: the rare-variant association with severe
      disease was not male-restricted, although clinically ascertained cases are. Graded
      INDIRECT because a sex-consistent burden statistic does not by itself establish
      the inheritance model.
  - reference: PMID:38481993
    reference_title: Gonadal androgens are associated with decreased type I interferon production by plasmacytoid dendritic cells and increased IgG titres to BNT162b2 following co-vaccination with live attenuated influenza vaccine in adolescents.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    quote_role: BACKGROUND
    snippet: "Mechanistically, women produce greater quantities of IFN-I since the upstream receptor, Toll-like receptor 7 (TLR7), is encoded by the X chromosome and escapes X chromosome inactivation in up to 30% of female immune cells"
    explanation: >-
      The gene-dosage reason a heterozygous woman is better buffered than a hemizygous
      man, which is the mechanism behind the male predominance. Graded with
      quote_role BACKGROUND because the citing study is an adolescent vaccination study
      and this sentence restates established pDC biology from prior work rather than
      reporting its own result; IN_VITRO because the underlying observation is in
      isolated human immune cells.
pathophysiology:
- name: TLR7 Loss of Function
  description: >-
    Hemizygous TLR7 variants that abolish or substantially reduce receptor function.
    The reported spectrum is broad in kind and consistent in consequence: frameshift
    and nonsense alleles that remove the protein (p.Asn158Thrfs*11, p.Leu227fs) or
    truncate it (p.Lys684*, p.Phe670Leufs*8), the four-nucleotide deletion
    p.Gln710Argfs*18 of the original Dutch kindred, and missense alleles expressed at
    normal levels that are nonetheless dead in a signalling assay (p.Val795Phe,
    p.His781Leu, p.Leu988Ser, p.Asn215Ser). Grading is biochemical, not predictive: of
    20 alleles found in one cohort of critical cases, 12 were loss-of-function, three
    hypomorphic and five neutral in an NF-kappaB reporter assay, so the functional
    test is what distinguishes a causal allele from a rare one.
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  genetic_context:
    variant_origin: GERMLINE
    zygosity: HEMIZYGOUS
    functional_impact_category: LOSS_OF_FUNCTION
  genes:
  - preferred_term: TLR7
    term:
      id: hgnc:15631
      label: TLR7
  molecular_functions:
  - preferred_term: TLR7 pattern recognition receptor activity
    term:
      id: GO:0038187
      label: pattern recognition receptor activity
    modifier: LOSS_OF_FUNCTION
  downstream:
  - target: Failure of Endosomal Single-Stranded RNA Sensing
    causal_link_type: DIRECT
    description: >-
      TLR7 is the receptor, so an allele that removes the protein or kills its
      signalling output removes the sensing step itself. The lesion is cell-intrinsic
      and reversible: re-expression of wild-type TLR7 in the patients' own cells
      restores the response, which is what establishes the variant as causal rather
      than correlated.
    evidence:
    - reference: PMID:34413140
      reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Hemizygosity for LOF TLR7 alleles thus abolished responses to TLR7 stimulation in EBV-B cells, a phenotype that was rescued by WT TLR7 expression."
      explanation: >-
        Loss of the allele abolishes the response and restoring the allele restores it,
        in the same patient cells - the direct form of this edge.
  evidence:
  - reference: PMID:32706371
    reference_title: Presence of Genetic Variants Among Young Men With Severe COVID-19.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rapid clinical whole-exome sequencing of the patients and segregation in available family members identified loss-of-function variants of the X-chromosomal TLR7."
    explanation: >-
      Identifies loss-of-function TLR7 alleles as the molecular lesion, from the study
      that first found the locus. The two specific genotypes named in this node's
      description (p.Gln710Argfs*18 and p.Val795Phe) are in the same abstract paragraph
      but are not quoted here, because the square brackets the source puts around the
      protein changes are stripped by the validator before matching.
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Twelve of the 20 alleles were loss-of-function (LOF) (including L988S in two patients, and M854I;L988S in another), three (p.L372M, p.I657T and p.P715S) were hypomorphic (activity < 25%), and the remaining five were neutral"
    explanation: >-
      The allelic grading this node rests on, and the reason a rare TLR7 variant is
      not by itself a diagnosis.
- name: Failure of Endosomal Single-Stranded RNA Sensing
  conforms_to: "innate_antiviral_interferon_response#Viral PAMP Sensing by Pattern-Recognition Receptors"
  description: >-
    TLR7 sits in the endosomal compartment and binds single-stranded RNA, including
    the SARS-CoV-2 genome delivered there by endocytosed virions. Without a functional
    receptor the ligand is not detected. The defect is specific to this receptor and
    not to endosomal sensing in general: the same patient pDCs respond normally to a
    TLR9 agonist, and no enrichment of deleterious variants was found at the adjacent
    X-linked gene TLR8.
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  cellular_components:
  - preferred_term: endosome
    term:
      id: GO:0005768
      label: endosome
  molecular_functions:
  - preferred_term: single-stranded RNA binding
    term:
      id: GO:0003727
      label: single-stranded RNA binding
    modifier: DECREASED
  biological_processes:
  - preferred_term: detection of virus
    term:
      id: GO:0009597
      label: detection of virus
    modifier: DECREASED
  - preferred_term: toll-like receptor 7 signaling pathway
    term:
      id: GO:0034154
      label: toll-like receptor 7 signaling pathway
    modifier: LOSS_OF_FUNCTION
  downstream:
  - target: Abolished MyD88-Dependent Signal Transduction
    causal_link_type: DIRECT
    description: >-
      Ligand binding is what recruits the MyD88 adaptor to the receptor's cytoplasmic
      TIR domain, so a receptor that does not engage its ligand never assembles the
      signalling complex. In silico modelling of the deleterious alleles reports the
      same thing from the protein side, with impaired binding of both viral RNA and
      MYD88.
    evidence:
    - reference: PMID:37567916
      reference_title: The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: COMPUTATIONAL
      snippet: "To conclude, TLR7 LOF mutations increase the risk of critical COVID-19 due to loss of viral RNA sensing ability and disrupted MyD88 signaling."
      explanation: >-
        Couples loss of RNA sensing to loss of MyD88 signalling. Graded COMPUTATIONAL
        and INDIRECT because the finding is a docking and binding-energy analysis of
        the variant proteins rather than a measurement in patient cells.
  evidence:
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "pDCs from P8 and P14 did not produce type I IFNs (or IL-6) upon stimulation with a TLR7 agonist, whereas they responded to a TLR9 agonist"
    explanation: >-
      The receptor-specific nature of the sensing failure: TLR7 agonist dead, TLR9
      agonist intact, in the same cells.
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "We observed no significant enrichment for coding non-synonymous variants of the X-linked gene TLR8"
    explanation: >-
      The negative control on the same chromosome, supporting the claim that the lesion
      is confined to TLR7 rather than to endosomal nucleic-acid sensing broadly.
- name: Abolished MyD88-Dependent Signal Transduction
  description: >-
    All TLR7 signalling runs through MyD88, and from there through IRAK4 to NF-kappaB
    and to the IRF7-dependent interferon arm. In TLR7-deficient cells this cascade is
    not engaged by TLR7 ligands. The reporter assay that grades the alleles reads
    NF-kappaB transcriptional activity, so the node is also the measurement the
    variant classification is built on; functionally, patient B cell lines fail to
    make TNF in response to TLR7 or TLR7/8 agonists.
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  biological_processes:
  - preferred_term: MyD88-dependent toll-like receptor signaling pathway
    term:
      id: GO:0002755
      label: MyD88-dependent toll-like receptor signaling pathway
    modifier: DECREASED
  - preferred_term: positive regulation of canonical NF-kappaB signal transduction
    term:
      id: GO:0043123
      label: positive regulation of canonical NF-kappaB signal transduction
    modifier: DECREASED
  downstream:
  - target: Deficient Plasmacytoid Dendritic Cell Type I Interferon Production
    causal_link_type: DIRECT
    description: >-
      In pDCs the MyD88 complex is coupled to constitutively high IRF7, which is why
      TLR7 ligation in these cells produces type I interferon rather than only
      inflammatory cytokines. With the adaptor step never reached, interferon induction
      does not occur.
    evidence:
    - reference: PMID:32706371
      reference_title: Presence of Genetic Variants Among Young Men With Severe COVID-19.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In primary peripheral blood mononuclear cells from the patients, downstream type I interferon (IFN) signaling was transcriptionally downregulated, as measured by significantly decreased mRNA expression of IRF7, IFNB1, and ISG15 on stimulation with the TLR7 agonist imiquimod as compared with family members and controls."
      explanation: >-
        Names the transcriptional step between the receptor and the interferon output,
        measured in the patients' own cells after TLR7 stimulation.
  - target: Impaired Type II Interferon Induction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The same stimulation that fails to induce type I interferon also fails to induce
      IFN-gamma, so the signalling block costs both interferon arms rather than only
      the type I response. The link is indirect: IFN-gamma in a stimulated mixed
      leukocyte population is produced by T and NK cells responding to accessory
      cytokines from the TLR7-bearing cells, not by MyD88 signalling in the
      IFN-gamma-producing cell itself, so the intermediate step is known but was not
      measured separately in these patients.
    evidence:
    - reference: PMID:32706371
      reference_title: Presence of Genetic Variants Among Young Men With Severe COVID-19.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The production of IFN-γ, a type II IFN, was decreased in patients in response to stimulation with imiquimod."
      explanation: Direct measurement of the type II interferon arm in patient cells.
  - target: Defective B Cell and Myeloid TLR7 Responsiveness
    causal_link_type: DIRECT
    description: >-
      TLR7 is expressed by B cells and by myeloid subsets as well as pDCs, and the
      adaptor block is the same in all of them, so the cellular phenotype extends
      beyond the interferon-producing compartment.
    evidence:
    - reference: PMID:34413140
      reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We also show that blood B cell lines and myeloid cell subsets from the patients do not respond to TLR7 stimulation, a phenotype rescued by wild-type TLR7"
      explanation: >-
        States the extension of the signalling defect to B cells and myeloid subsets,
        with the wild-type rescue that makes it attributable to TLR7.
  evidence:
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In response to agonists of TLR7 (imiquimod) or TLR7 plus TLR8 (R848), the EBV-B cell lines carrying these two mutations failed to produce TNF"
    explanation: >-
      The functional readout of the abolished cascade in patient-derived cells, using
      an NF-kappaB-dependent output.
  - reference: PMID:34952932
    reference_title: Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our investigation revealed a profound impairment of the TLR7 pathway in patients carrying loss-of-function variants."
    explanation: >-
      Independent transcriptome-wide confirmation that the pathway, not merely one
      readout, is impaired in carriers of loss-of-function alleles.
- name: Deficient Plasmacytoid Dendritic Cell Type I Interferon Production
  conforms_to: "innate_antiviral_interferon_response#Type I and III Interferon Induction and JAK-STAT Signaling"
  description: >-
    The central node. pDCs are the body's dominant source of type I interferon on
    nucleic-acid sensing, producing 100 to 1,000 times more per cell than any other
    leukocyte subset after TLR7 stimulation, and they are the cell type in which TLR7
    deficiency matters. Patient pDCs infected with SARS-CoV-2 induce the type I
    interferon gene module 10 to 100 times more weakly than control pDCs and fail to
    mature into the PD-L1-high S1 subset that produces most of the IFN-alpha. The
    defect is partial rather than absolute, which the discovery study attributes to
    TLR7-independent sensors, TLR9 among them. pDC numbers themselves are normal:
    deep immunophenotyping found no abnormality in the leukocyte subsets, so this is a
    functional and not a numerical defect. The module node this conforms to bundles
    interferon induction with downstream JAK-STAT signalling, and only the induction
    half is lost here: the interferon receptor and its JAK-STAT machinery are intact
    in TLR7 deficiency, which is what makes exogenous interferon a rational
    replacement rather than a futile one.
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  cell_types:
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
  biological_processes:
  - preferred_term: type I interferon production
    term:
      id: GO:0032606
      label: type I interferon production
    modifier: DECREASED
  - preferred_term: positive regulation of type I interferon production
    term:
      id: GO:0032481
      label: positive regulation of type I interferon production
    modifier: DECREASED
  downstream:
  - target: Unrestrained Early SARS-CoV-2 Replication in the Respiratory Tract
    causal_link_type: DIRECT
    description: >-
      Type I interferon is what restricts SARS-CoV-2 in the respiratory tract in the
      first days of infection. Without the pDC-derived burst the virus is not
      contained early, and the pDC compartment cannot be substituted for, because TLR7
      is not expressed by lung or pulmonary epithelial cells and so the epithelial
      TLR3 arm of interferon immunity does not cover this lesion.
    evidence:
    - reference: PMID:34413140
      reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Human TLR7 and pDCs are essential for protective type I IFN immunity against SARS-CoV-2 in the respiratory tract."
      explanation: >-
        The conclusion of the discovery study, stating the non-redundancy of this
        pathway for control of the virus at the site of disease.
    - reference: PMID:34413140
      reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "Our study indicates that pulmonary epithelial cells are not sufficient for host defense against SARS-CoV-2, as these cells do not express TLR7."
      explanation: >-
        Why no compensating source exists at the affected site, which is the reason a
        blood-cell defect produces a lung disease.
  evidence:
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Induction of the 17 type I IFN genes in pDCs from TLR7-deficient patients was 10 to 100 times weaker than that in pDCs from healthy individuals"
    explanation: >-
      The quantitative core of this node, measured in patient pDCs infected with
      SARS-CoV-2 itself rather than with a synthetic agonist.
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We confirmed that pDCs produced 100-1,000 times more type I IFN per cell than other leukocyte subsets upon TLR7 stimulation"
    explanation: >-
      Establishes why the pDC is the cell that matters here, and why loss of its
      response is not covered by the other TLR7-expressing subsets.
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Deep immunophenotyping by CyTOF in seven patients with TLR7 deficiency revealed no major abnormalities in 18 peripheral blood leukocyte subsets, including pDCs, mDCs, monocytes, and B cells"
    explanation: >-
      Supports the claim that this is a functional rather than a numerical defect, and
      is the reason a blood count does not screen for the condition.
- name: Impaired Type II Interferon Induction
  description: >-
    TLR7 stimulation of patient cells also fails to raise IFN-gamma. This arm is
    affected across the allelic spectrum rather than only in null alleles: a
    transcriptomic study of stimulated patient PBMCs found the failure of IFN-gamma
    upregulation even in cells carrying hypofunctional and hypomorphic variants that
    retain measurable NF-kappaB activity. It is recorded as a separate node because it
    is a distinct measured output of the same signalling block, and because it is what
    distinguishes TLR7 deficiency from a pure type I interferonopathy.
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  biological_processes:
  - preferred_term: type II interferon production
    term:
      id: GO:0032609
      label: type II interferon production
    modifier: DECREASED
  evidence:
  - reference: PMID:34952932
    reference_title: Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Of note, a failure in IFNγ upregulation following stimulation was also observed in cells harboring the hypofunctional and hypomorphic variants."
    explanation: >-
      The claim that this node makes beyond the type I arm: the type II defect extends
      to alleles that are not outright null.
  - reference: PMID:34367187
    reference_title: Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Functional testing of this variant revealed decreased type I and II interferon responses in peripheral mononuclear blood cells upon stimulation with the TLR7 agonist imiquimod, confirming a loss-of-function effect."
    explanation: >-
      Independent replication in a separate kindred that both interferon arms are
      affected by a TLR7 missense allele.
- name: Defective B Cell and Myeloid TLR7 Responsiveness
  description: >-
    B cells and myeloid subsets (classical, intermediate and non-classical monocytes,
    myeloid dendritic cells) express TLR7 and are unresponsive to TLR7 ligands in
    these patients. What this costs clinically is not settled. In mice, B-cell-intrinsic
    Tlr7 signalling is required for germinal-centre-dependent class-switched
    neutralising antibody against SARS-CoV-2; in TLR7-deficient humans given a
    SARS-CoV-2 mRNA vaccine, the memory B cell and neutralising IgG response is
    essentially normal. The node is therefore recorded with the cellular defect
    established and the humoral consequence held open; see the HUMAN_MODEL_MISMATCH
    discussion.
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: classical monocyte
    term:
      id: CL:0000860
      label: classical monocyte
  - preferred_term: myeloid dendritic cell
    term:
      id: CL:0000782
      label: myeloid dendritic cell
  biological_processes:
  - preferred_term: toll-like receptor 7 signaling pathway
    term:
      id: GO:0034154
      label: toll-like receptor 7 signaling pathway
    modifier: LOSS_OF_FUNCTION
  evidence:
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Human TLR7 is known to be expressed and functional only in leukocyte subsets: plasmacytoid and classical dendritic cells (pDCs and mDCs), monocytes (classical, intermediate, and non-classical), and B cells"
    explanation: The expression pattern that defines which cells this node covers.
  - reference: PMID:36342455
    reference_title: Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "The receptor-binding domain spike protein (RBD)-specific memory B cell response in all patients was quantitatively and qualitatively similar to healthy donors."
    explanation: >-
      Refutes the stronger reading of this node - that the B cell defect translates
      into a defective humoral response in humans. Recorded here rather than omitted
      because it is the reason the node's confidence is PROVISIONAL.
- name: Unrestrained Early SARS-CoV-2 Replication in the Respiratory Tract
  description: >-
    With the interferon brake absent in the first days of infection, viral replication
    is not contained. This step is inferred in humans from the interferon defect and
    the clinical outcome rather than measured directly in patients' airways; the viral
    load measurement comes from TLR7-deficient mice, in which lung virus titres rise
    together with loss of lung type I and type III interferon and interferon-stimulated
    gene expression. The type III interferon loss is recorded on this node because the
    murine lung is where it was measured; no type III measurement exists in
    TLR7-deficient patients.
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  biological_processes:
  - preferred_term: viral genome replication
    term:
      id: GO:0019079
      label: viral genome replication
    modifier: INCREASED
  - preferred_term: defense response to virus
    term:
      id: GO:0051607
      label: defense response to virus
    modifier: DECREASED
  - preferred_term: type III interferon production
    term:
      id: GO:0034343
      label: type III interferon production
    modifier: DECREASED
  downstream:
  - target: Severe viral infection
    causal_link_type: DIRECT
    description: >-
      The disease-defining susceptibility, expressed clinically as severe infection
      with one specific virus rather than broad viral susceptibility. The edge is drawn
      from the failure of viral containment rather than from the pneumonia node, which
      is one expression of that severe infection rather than its cause.
    evidence:
    - reference: PMID:34413140
      reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Overall, X-linked recessive TLR7 deficiency is a highly penetrant genetic etiology of critical COVID-19 pneumonia, in about 1.8% of male patients below the age of 60 years."
      explanation: The headline causal claim linking this genotype to severe viral disease.
  - target: Hypoxemic COVID-19 Pneumonia
    causal_link_type: DIRECT
    description: >-
      Uncontrolled replication in the lower respiratory tract is what produces the
      pneumonia the patients present with. The clinical arm of this edge is the
      ascertainment itself: deleterious TLR7 alleles were enriched among men with
      critical COVID-19 pneumonia and absent from asymptomatically or mildly infected
      men of comparable age.
    evidence:
    - reference: PMID:34413140
      reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "None of the 331 asymptomatically or mildly infected male individuals aged 1.3 to 102 years (mean: 38.7 years) tested carry such TLR7 variants"
      explanation: >-
        The case-control contrast underlying the edge: the genotype is found in the
        severe arm and not in the mild arm of the same infection.
  - target: Lung Neutrophil Accumulation and Immunopathology
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      A higher and more prolonged viral burden drives the inflammatory infiltrate that
      damages the lung. Demonstrated in TLR7-deficient mice, where the increased virus
      load is accompanied by neutrophil accumulation and worse lung pathology; the
      intermediate chemotactic steps are known but were not measured in patients.
    evidence:
    - reference: PMID:40162785
      reference_title: Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      snippet: "A detailed evaluation of MA-CoV-2-infected lungs revealed increased neutrophil accumulation and lung pathology in TLR7-/- mice."
      explanation: >-
        The histological consequence of the uncontained infection, in the mouse model
        of this lesion. INDIRECT because the inference to human disease crosses species.
  evidence:
  - reference: PMID:40162785
    reference_title: Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "We showed that TLR7 deficiency significantly increased lung virus loads and morbidity/mortality, which correlated with reduced levels of type I IFNs (Ifna/b), type III IFNs (Ifnl), and IFN-stimulated genes (ISGs) in the lungs."
    explanation: >-
      The direct measurement of the viral-control failure that human studies infer, in
      a TLR7-null animal challenged with a mouse-adapted SARS-CoV-2.
  - reference: PMID:39289468
    reference_title: Deficiency of Tlr7 and Irf7 in mice increases the severity of COVID-19 through the reduced interferon production.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "The deficiency of Tlr7 and Irf7 globally and/or in immune cells in mice increases the severity of COVID-19 via impaired IFN activation in both immune and/or non-immune cells, leading to increased lung viral loads."
    explanation: >-
      Independent mouse replication linking the interferon defect to viral load and to
      severity, with bone-marrow chimeras locating the requirement in immune cells.
- name: Lung Neutrophil Accumulation and Immunopathology
  description: >-
    Neutrophil infiltration and inflammatory lung pathology in a lung in which the
    virus was never brought under control. The histology is murine: increased
    neutrophil accumulation and lung pathology in TLR7-null mice, with viral antigen
    in macrophages, pneumocytes and bronchial epithelial cells. No histological series
    from TLR7-deficient human lungs exists, so nothing more specific about the human
    lesion is asserted here. The sequence matters for how the disease is
    read: the inflammation here is downstream of a failed antiviral response, not of an
    excessive innate response, so TLR7-deficient patients are not interferonopathy
    patients and the mechanistic argument for immunosuppression as the primary
    intervention is weaker than in unselected severe COVID-19.
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  cell_types:
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  - preferred_term: alveolar macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  - preferred_term: pulmonary alveolar type 2 cell
    term:
      id: CL:0002063
      label: pulmonary alveolar type 2 cell
  biological_processes:
  - preferred_term: neutrophil chemotaxis
    term:
      id: GO:0030593
      label: neutrophil chemotaxis
    modifier: INCREASED
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  downstream:
  - target: Acute respiratory distress syndrome
    causal_link_type: DIRECT
    description: >-
      Alveolar injury with inflammatory infiltrate is the lesion underlying the
      hypoxaemic respiratory failure that defines critical disease in these patients.
    evidence:
    - reference: PMID:40162785
      reference_title: Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      snippet: "we conclusively demonstrated that despite TLR7-induced robust lung inflammation, TLR7-induced IFN/ISG responses suppress lung virus replication and pathology and provide protection against SARS-CoV-2-induced fatal pneumonia"
      explanation: >-
        States the direction of the relationship this edge asserts - that losing TLR7
        worsens lung pathology and mortality despite TLR7 itself being inflammatory.
  evidence:
  - reference: PMID:40162785
    reference_title: Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "Moreover, immunohistochemical assessment of the lungs revealed increased numbers of SARS-CoV-2 antigen-positive macrophages, pneumocytes, and bronchial epithelial cells in TLR7-/- and IFNAR-deficient mice compared to control mice."
    explanation: >-
      The cell types carrying viral antigen in the affected lung, which is why this
      node binds alveolar macrophage and type 2 pneumocyte alongside the neutrophil it
      is named for.
- name: Hypoxemic COVID-19 Pneumonia
  description: >-
    The clinical endpoint: pneumonia requiring oxygen, progressing in most reported
    patients to high-flow oxygen or mechanical ventilation. Across the discovery
    cohort the patients were aged 7 to 71 years with a mean of 34.4 years, markedly
    younger than the cohort they were drawn from, and two of sixteen died. Severity is
    graded rather than binary - the same allele produced critical pneumonia in one
    hemizygous relative, severe pneumonia in another, and asymptomatic infection in a
    third - which is the incomplete penetrance this entry records as a hypothesis
    rather than a settled quantity.
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  downstream:
  - target: Pneumonia
    causal_link_type: DIRECT
    description: >-
      Pneumonia is the organ manifestation in every reported symptomatic case; the
      cohorts were assembled on it.
    evidence:
    - reference: PMID:34413140
      reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We report very rare, biochemically deleterious X-linked TLR7 variants in 16 unrelated male individuals aged 7 to 71 years (mean: 36.7 years) from a cohort of 1,202 male patients aged 0.5 to 99 years (mean: 52.9 years) with unexplained critical COVID-19 pneumonia."
      explanation: Identifies critical COVID-19 pneumonia as the presenting illness.
  - target: Hypoxemia
    causal_link_type: DIRECT
    description: >-
      The pneumonia is hypoxaemic by definition of the cohorts: severe disease was
      defined by a low-flow oxygen requirement and critical disease by high-flow oxygen
      or ventilation.
    evidence:
    - reference: PMID:34413140
      reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This study included 1,202 male patients with life-threatening COVID-19 pneumonia, defined as patients with pneumonia who developed critical disease, whether pulmonary with high-flow oxygen (> 6L/min) or mechanical ventilation (CPAP, BIPAP, intubation), septic shock, or any other type of organ damage requiring ICU admission."
      explanation: >-
        The oxygen-requirement definition that makes hypoxaemia constitutive of the
        phenotype rather than an occasional complication.
  - target: Respiratory failure requiring assisted ventilation
    causal_link_type: DIRECT
    description: >-
      Progression to mechanical ventilation was the presentation in the index kindreds
      and is the usual course of the critical form.
    evidence:
    - reference: PMID:32706371
      reference_title: Presence of Genetic Variants Among Young Men With Severe COVID-19.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "They were previously well before developing respiratory insufficiency due to severe COVID-19, requiring mechanical ventilation in the ICU."
      explanation: >-
        The ventilation requirement in the four index patients, all previously healthy
        young men.
  evidence:
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patients were aged 7 to 71 years and their mean age was lower than that of the total cohort (mean age of 34.4 years, versus 52.9 years for the total cohort, in which age ranged from 0.5 to 99 years). TLR7-deficient patients accounted for about 1.8% of the patients below the age of 60 years (15 patients) and 1.3% of the entire cohort (16 patients). Two patients died and 14 survived"
    explanation: >-
      The age distribution and outcome of the defined cohort, and the source of the
      age figures in this node's description.
mechanistic_hypotheses:
- hypothesis_group_id: age_dependent_penetrance_pdc
  hypothesis_label: Declining plasmacytoid dendritic cell numbers explain why penetrance rises with age
  status: EMERGING
  description: >-
    Penetrance of TLR7 deficiency for severe or critical COVID-19 is high but
    incomplete, and the exceptions are mostly young. Among the hemizygous relatives
    identified by family screening, the three with asymptomatic, mild or moderate
    infection were aged 5, 5 and 38 years, while those with severe or critical
    pneumonia were older on average (mean 32.4 years against 16), though that group
    spans 7 to 71 years and includes children. The discovery study proposes that because blood pDC counts
    fall with age, a young TLR7-deficient boy still has enough pDC-independent or
    residual TLR9-driven interferon capacity to contain the virus, while the same
    genotype in an adult does not. A second, non-exclusive proposal from the same study
    is that genetic or epigenetic variation in TLR9 responses modifies the phenotype,
    since patient pDCs respond normally to TLR9 agonists. Which is right determines
    whether a hemizygous child identified by family screening should be counselled as
    being at risk now or as becoming at risk later.
  evidence:
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 23 male patients carrying deleterious alleles of TLR7 infected with SARS-CoV-2, the 20 patients who developed severe (n=3) or critical (n=17) COVID-19 were aged 7-71 years (mean: 32.4 years) whereas the three patients who developed asymptomatic, mild, or moderate infection were younger: 5, 5, and 38 years (mean: 16 years)."
    explanation: The age contrast between penetrant and non-penetrant carriers that the hypothesis is built on.
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Blood pDC counts decrease with age (36–38), and this may contribute to the apparent increase in penetrance with age."
    explanation: >-
      The proposed mechanism, stated by the authors as a possibility rather than a
      finding - which is why this is recorded as EMERGING. Graded OTHER with a
      REVIEW_SYNTHESIS quote role because the sentence cites prior pDC-ageing work
      rather than reporting a measurement made in this study.
  - reference: PMID:35708626
    reference_title: Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The penetrance of AR IFNAR1 and IRF7 deficiencies for critical COVID-19 appears to be complete, whereas that of XR TLR7 deficiency is high, but incomplete, especially in young patients"
    explanation: >-
      Independent statement of the age-skewed incomplete penetrance, contrasted against
      interferon-pathway defects whose penetrance is complete.
phenotypes:
- category: Immunological
  name: Severe viral infection
  description: >-
    Susceptibility to severe disease from SARS-CoV-2, and - as far as the reported
    patients go - from that virus alone. None of the index patients had previously been
    hospitalised for a severe viral illness including influenza pneumonia, despite
    serological evidence of prior infection with diverse viruses, so the ontology term
    is bound for the SARS-CoV-2 susceptibility the entry is about rather than to assert
    a broad antiviral defect.
  phenotype_term:
    preferred_term: Severe SARS-CoV-2 infection
    term:
      id: HP:0031691
      label: Severe viral infection
  evidence:
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "None had previously been hospitalized for a severe viral illness, including influenza pneumonia. This cohort of patients thus suggests that TLR7 deficiency does not underlie severe disease caused by common viral infections other than SARS-CoV-2, or if so, with lower penetrance."
    explanation: >-
      Supports the narrow reading recorded in this phenotype's description, and is the
      reason the HP binding is qualified in preferred_term rather than taken broadly.
  - reference: PMID:35748970
    reference_title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "X-linked TLR7 deficiency represents a novel IEI predisposing to severe COVID-19."
    explanation: >-
      The IUIS committee's own statement of the susceptibility, which is what places
      this disorder in the innate-immunity-defect category recorded above.
- category: Respiratory
  name: Pneumonia
  description: >-
    SARS-CoV-2 pneumonia is the presenting and defining illness. Every symptomatic
    patient in the discovery and replication cohorts had pneumonia; the cohorts were
    assembled on it, which means the frequency recorded here is conditional on
    ascertainment and is not an estimate of risk in an unselected hemizygote.
  phenotype_term:
    preferred_term: SARS-CoV-2 pneumonia
    term:
      id: HP:0002090
      label: Pneumonia
  evidence:
  - reference: PMID:33650967
    reference_title: "Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overall, we found TLR7 deleterious variants in 2.1% of severely affected males and in none of the asymptomatic participants."
    explanation: >-
      Independent Italian replication of the enrichment of deleterious alleles in
      severe disease and their absence from asymptomatic infection.
- category: Respiratory
  name: Hypoxemia
  description: >-
    Low arterial oxygen saturation is what defines the clinical categories these
    patients fall into: severe disease was defined by a low-flow oxygen requirement
    (under 6 L/min) and critical disease by high-flow oxygen, non-invasive or invasive
    ventilation.
  phenotype_term:
    preferred_term: Hypoxemia
    term:
      id: HP:0012418
      label: Hypoxemia
  evidence:
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study also included patients with severe COVID-19 pneumonia, defined as hospitalized patients with pneumonia that required low-flow oxygen (<6L/min); moderate COVID-19 pneumonia, defined as patients with pneumonia but did not require oxygen therapy"
    explanation: >-
      The oxygen-requirement thresholds that the severity grading, and so this
      phenotype, rest on.
- category: Respiratory
  name: Respiratory failure requiring assisted ventilation
  description: >-
    Progression to mechanical ventilation. All four patients of the two index Dutch
    kindreds required it, with a mean of ten days of ventilatory support and thirteen
    days in intensive care, and one died.
  phenotype_term:
    preferred_term: Respiratory failure requiring assisted ventilation
    term:
      id: HP:0004887
      label: Respiratory failure requiring assisted ventilation
  evidence:
  - reference: PMID:32706371
    reference_title: Presence of Genetic Variants Among Young Men With Severe COVID-19.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mean duration of ventilatory support was 10 days (range, 9-11); the mean duration of ICU stay was 13 days (range, 10-16). One patient died."
    explanation: >-
      Quantifies the ventilation requirement and outcome in the index patients, which
      is the basis for this phenotype and for its severity.
- category: Respiratory
  name: Acute respiratory distress syndrome
  description: >-
    Hypoxaemic respiratory failure meeting the accepted ARDS criteria, with bilateral
    ground-glass opacification and consolidation on imaging. Recorded for the critical
    form of the disease, which the discovery cohort defined by ICU-level organ support;
    one reported patient deteriorated far enough to be referred for extracorporeal
    membrane oxygenation.
  phenotype_term:
    preferred_term: Acute respiratory distress syndrome
    term:
      id: HP:0033677
      label: Acute respiratory distress syndrome
  evidence:
  - reference: PMID:34367187
    reference_title: Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A CT-scan showed multiple diffuse ground-glass opacities and consolidations in all lung segments, meeting the criteria for ARDS."
    explanation: >-
      Records the ARDS diagnosis itself, in a genetically confirmed patient and against
      the criteria the same paper cites (the Berlin definition).
  - reference: PMID:34367187
    reference_title: Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Despite this therapeutic regiment, the patient's condition further deteriorated and he was referred to the Erasmus Medical Center for possible ECMO treatment."
    explanation: >-
      Supports the severity statement in this phenotype's description rather than the
      diagnosis: progression to the degree of respiratory failure for which
      extracorporeal support is considered.
genetic:
- name: TLR7
  gene_term:
    preferred_term: TLR7
    term:
      id: hgnc:15631
      label: TLR7
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  frequency: >-
    Deleterious hemizygous alleles in about 1.8% of male patients under 60 with
    critical COVID-19 pneumonia; cumulative allele frequency below 6.5 per 10,000 men
    in the general population.
  notes: >-
    TLR7 is the single causal gene; the disorder is genetically homogeneous by
    construction, having been found by an X-chromosome-wide enrichment test in which
    TLR7 was the only gene to survive correction for multiple testing. Alleles are
    private or very rare and span frameshift, nonsense and missense classes, and are
    graded functionally rather than by prediction: in the discovery cohort 12 of 20
    were loss-of-function and three hypomorphic, with five neutral alleles excluded
    from the diagnosis. A separate Spanish series found that common TLR7 variants
    (rs179008, rs179009, rs3853839) also associate with severe pneumonia, which is a
    susceptibility rather than a Mendelian claim and is not what this entry curates.
  evidence:
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "TLR7 was the highest ranked of these genes (uncorrected P-value = 3.5×10−5) and the only gene that remained significant after correction for multiple testing"
    explanation: >-
      The unbiased genome-level result that identifies TLR7 as the locus, rather than a
      candidate-gene assertion.
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Each of these 24 deleterious variants had an individual MAF < 1.3x10-4 in men and their cumulative MAF in men was 6.5 x10-4"
    explanation: >-
      The population allele frequency that makes a deleterious hemizygous variant in a
      young man with critical COVID-19 interpretable as causal.
  - reference: PMID:40423910
    reference_title: "From Rare to Common: Genetic Insights into TLR7 Variants in a Multicentric Spanish Study on COVID-19 Severity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The functional impact of rare TLR7 variants was assessed using a luciferase reporter assay and revealed that N215S is a loss-of-function (LOF) variant, while D332G exhibits an hypomorphic behavior."
    explanation: >-
      Independent functional grading of further alleles, and the reason the
      loss-of-function/hypomorphic distinction is recorded as part of the genetic claim
      rather than assumed from the variant class.
  - reference: PMID:40423910
    reference_title: "From Rare to Common: Genetic Insights into TLR7 Variants in a Multicentric Spanish Study on COVID-19 Severity."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition, the common variants Q11L (rs179008), c.4-151A>G (rs179009) and c.*881C>G (rs3853839) were associated with severe pneumonia, while c.4-151A>G (rs179009) was specifically linked to Intensive Care Unit (ICU) admission."
    explanation: >-
      The common-variant association named in this record's notes and explicitly
      excluded from the Mendelian claim; INDIRECT because an association at a common
      allele does not establish the monogenic disorder.
  - reference: PMID:37020259
    reference_title: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes can underlie life-threatening COVID-19, particularly with recessive inheritance, in patients under 60 years old."
    explanation: >-
      A genome-wide rare-variant burden analysis in 3,269 patients independently
      recovering TLR7 as the leading recessive signal.
  - reference: PMID:36327219
    reference_title: "Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75-10.05, p = 5.41x10-7)."
    explanation: >-
      The population-scale effect size, from a 21-cohort exome-wide burden meta-analysis
      across 12 countries. It is a different estimand from the diagnostic yields under
      prevalence: an odds ratio over all rare deleterious carriers, not the proportion
      of severe cases a functionally confirmed diagnosis explains.
prevalence:
- population: >-
    Male patients under 60 years with critical COVID-19 pneumonia, COVID Human Genetic
    Effort international cohort
  measure_type: PERIOD_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 1800.0
  notes: >-
    Not a population prevalence. This is the proportion of a clinically defined group -
    unrelated male patients below 60 with unexplained critical COVID-19 pneumonia - who
    carry a biochemically deleterious hemizygous TLR7 allele (1.8%, 15 of the
    patients in that age band). It is the figure a clinician uses to decide whether to
    sequence TLR7 in such a patient, and it is conditional on the pandemic exposure.
  evidence:
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overall, by disrupting pDC-dependent type I IFN production, XR TLR7 deficiency accounts for at least 1% of cases of life-threatening COVID-19 pneumonia in men under 60."
    explanation: The authors' own summary of the diagnostic yield in this clinical group.
- population: >-
    Young (under 60) severe COVID-19 cases with no reported clinical risk factors,
    Spanish and Italian case-control series
  measure_type: PERIOD_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 2400.0
  notes: >-
    2.4% of 378 young cases without clinical risk factors, against 0.24% of
    population-based controls. Replicates the discovery-cohort yield in an independent
    ascertainment and supplies the effect size (odds ratio 12.3, rising on
    incorporation of functional or structural evidence).
  evidence:
  - reference: PMID:38944683
    reference_title: Stratified analyses refine association between TLR7 rare variants and severe COVID-19.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rare deleterious TLR7 variants were present in 2.4% of young (<60 years) cases with no reported clinical risk factors (n = 378), compared to 0.24% of controls"
    explanation: The case and control proportions this record reports.
- population: Males in the general population (gnomAD v2.1), deleterious TLR7 alleles
  measure_type: CARRIER_FREQUENCY
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 65.0
  rate_denominator: POPULATION
  notes: >-
    Cumulative minor allele frequency of the 24 biochemically deleterious TLR7 alleles
    in men, 6.5 per 10,000, equivalent to 65 per 100,000. Because TLR7 is X-linked and
    these are hemizygous states in males, the allele frequency is also the frequency of
    affected genotypes in men. The strictly loss-of-function subset (excluding
    hypomorphs) is about 2.2 per 10,000.
  evidence:
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The cumulative allele frequency for deleterious TLR7 variants in the male general population is < 6.5x10-4"
    explanation: The source of the 65 per 100,000 figure normalized in this record.
- population: Children under 16 hospitalized for COVID-19 pneumonia, international cohort
  measure_type: PERIOD_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 6250.0
  notes: >-
    Seven of 112 children (6.25%) hospitalized for COVID-19 pneumonia had X-linked
    recessive TLR7 deficiency, which made it the single commonest inborn error of type
    I interferon immunity in that paediatric series. Reported here because it is a
    different clinical group from the adult cohorts above, not because the disorder is
    commoner in children overall.
  evidence:
  - reference: PMID:35708626
    reference_title: Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In an international cohort of 112 children (<16 yr old) hospitalized for COVID-19 pneumonia, we report 12 children (10.7%) aged 1.5-13 yr with critical (7 children), severe (3), and moderate (2) pneumonia and 4 of the 15 known clinically recessive and biochemically complete inborn errors of type I IFN immunity: X-linked recessive TLR7 deficiency (7 children) and autosomal recessive IFNAR1 (1), STAT2 (1), or TYK2 (3) deficiencies"
    explanation: >-
      Gives both the denominator (112 children) and the count of TLR7-deficient
      children (7) from which the 6.25% in this record is taken.
diagnosis:
- name: TLR7 sequencing in a young man with unexplained severe COVID-19
  description: >-
    The diagnostic entry point. Because the genotype is clinically silent before
    infection, the disorder is found by sequencing TLR7 in a male patient whose severe
    COVID-19 is not explained by age or comorbidity, and the finding is then confirmed
    functionally.
  diagnosis_term:
    preferred_term: Genetic Testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:34367187
    reference_title: Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study supports a rationale for the genetic screening for TLR7 variants in young men with severe COVID-19 in the absence of other relevant risk factors."
    explanation: The stated indication for testing, from the prospective screening study.
- name: Functional confirmation of a candidate TLR7 allele
  description: >-
    A rare TLR7 variant is not a diagnosis on its own: five of twenty alleles found in
    critical cases were neutral in a signalling assay, and four of eight previously
    published variants were likewise neutral. Confirmation is a signalling readout - an
    NF-kappaB reporter assay on the transfected allele, or loss of the TLR7-agonist
    response in the patient's own cells, with rescue by wild-type TLR7.
  diagnosis_term:
    preferred_term: luciferase reporter signalling assay on the transfected TLR7 allele
  evidence:
  - reference: PMID:40423910
    reference_title: "From Rare to Common: Genetic Insights into TLR7 Variants in a Multicentric Spanish Study on COVID-19 Severity."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The luciferase assay proves to be a reliable tool for evaluating TLR7 signaling, effectively distinguishing between neutral, LOF, and gain-of-function (GOF) variants."
    explanation: >-
      Names the assay and states what it discriminates, which is the step that converts
      a rare variant into a diagnosis.
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Collectively, these findings suggest that 16 of the 21 patients in our cohort (Table 1), as well as only 6 of the previously reported 12 patients carry deleterious TLR7 variants."
    explanation: >-
      Quantifies how much reclassification functional testing produces, including the
      halving of previously published diagnoses - the reason this step is listed
      separately.
  notes: >-
    No NCIT clinical-action term was bound for this assay. Searched the committed NCIT
    label cache with
    grep -i -E ",(Luciferase|Reporter Gene|Reporter Assay|Signal Transduction Assay)," cache/ncit/terms.csv,
    which returned nothing, and the OLS NCIT search for "Luciferase Reporter Assay",
    which returns substance and gene-product terms rather than a clinical intervention
    reachable from NCIT:C25218. The preferred_term is left free-text rather than bound
    to a broader procedure term that would lose the specificity.
treatments:
- name: SARS-CoV-2 mRNA vaccination
  description: >-
    The one intervention with both a mechanistic rationale and direct supporting data
    in this disorder. Because TLR7 deficiency is clinically silent until infection,
    prophylaxis is what changes the outcome, and it was applied this way in practice:
    hemizygous relatives identified by family screening were fast-tracked for early
    vaccination. The rationale is not obvious a priori - TLR7 senses single-stranded RNA
    and an mRNA vaccine delivers it - so the key observation is that the humoral
    response to mRNA vaccination in TLR7-deficient patients is essentially normal in
    amplitude, duration and neutralising capacity, which the authors read as showing
    that induction of type I interferon is not required for an efficient humoral
    response to an mRNA vaccine. Whether the nucleoside-modified mRNA is sensed by
    endosomal TLRs at all is left open in their discussion, which notes that modified
    mRNA may still be partially recognised by those receptors, so the normal response
    is not explained here by assuming the vaccine bypasses TLR7.
  treatment_term:
    preferred_term: Vaccination
    term:
      id: NCIT:C15346
      label: Vaccination
    therapeutic_agent:
    - preferred_term: mRNA COVID-19 vaccine
      term:
        id: NCIT:C181140
        label: mRNA COVID-19 Vaccine
  therapeutic_modality: VACCINE
  target_mechanisms:
  - target: Unrestrained Early SARS-CoV-2 Replication in the Respiratory Tract
    description: >-
      Vaccination does not repair the TLR7 lesion. It supplies adaptive immunity that
      acts in place of the missing innate interferon brake, so that the virus is met by
      pre-existing neutralising antibody rather than by an interferon response that
      cannot be mounted.
    evidence:
    - reference: PMID:36342455
      reference_title: Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The amplitude and duration of, and viral neutralization by, RBD-specific IgG serological response were also largely unaffected by TLR7, IRF7, or IFNAR1 deficiencies up to 7 mo after vaccination in all patients."
      explanation: >-
        Establishes that the protective arm vaccination relies on is intact in
        TLR7-deficient patients, which is what makes this a usable intervention rather
        than a hopeful one.
  evidence:
  - reference: PMID:34367187
    reference_title: Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Based on the TLR7 variant carriership, these individuals were fast-tracked for early vaccination."
    explanation: >-
      Documents the intervention being applied on the basis of the genetic diagnosis in
      identified hemizygous relatives.
  - reference: PMID:36342455
    reference_title: Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These results suggest that induction of type I IFN is not required for efficient generation of a humoral response against SARS-CoV-2 by mRNA vaccines."
    explanation: >-
      The general form of the finding: the vaccine's mechanism does not run through the
      pathway that is broken in these patients.
- name: Genetic counseling and pre-symptomatic testing of male relatives
  description: >-
    The diagnosis in a proband makes the family actionable, which is unusual for a
    disease defined by an exposure. Mothers are typically heterozygous carriers and
    hemizygous male relatives can be identified before they are infected, which is what
    allows prophylaxis to be offered to the people who need it. Family screening in the
    discovery cohort identified 16 heterozygous women and seven hemizygous men beyond
    the index cases.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:34367187
    reference_title: Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A diagnosis of TLR7 deficiency could not only inform on treatment options for the patient, but also enables pre-symptomatic testing of at-risk male relatives with the possibility of instituting early preventive and therapeutic interventions."
    explanation: States the purpose of cascade testing in this disorder.
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sanger sequencing of the TLR7 locus in the relatives of these patients identified the deleterious alleles in 16 heterozygous women from eleven families and seven hemizygous men from seven families"
    explanation: >-
      The yield of cascade testing in the reported families, which is the quantitative
      case for doing it.
- name: Early exogenous interferon therapy
  description: >-
    Mechanistically the obvious replacement: the lesion is a failure to produce type I
    interferon in a cell type whose receptor pathway is intact, so exogenous interferon
    bypasses the defect. It is a rational option rather than a demonstrated one - no
    trial or case series in TLR7-deficient patients supports it, and the argument is
    carried over from inborn errors of interferon signalling in general. Recorded here
    because the reasoning is explicit in the clinical literature on this disorder, and
    flagged as unproven because it is.

    The nearest randomised evidence comes from genotype-unselected COVID-19 trials of
    pegylated interferon lambda, a type III interferon, and its lesson is about timing
    rather than about this genotype. A single early subcutaneous dose in outpatients
    within seven days of symptom onset halved hospitalisation or emergency attendance,
    while two doses given to patients already admitted to hospital produced no benefit.
    If that time dependence carries over, it is awkward for this disorder specifically:
    TLR7-deficient patients are found because they are already critically ill, which is
    the window in which interferon did not work.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: recombinant interferon beta
      term:
        id: NCIT:C495
        label: Recombinant Interferon Beta
    - preferred_term: pegylated interferon lambda-1a
      term:
        id: NCIT:C166435
        label: Peginterferon Lambda-1A
  therapeutic_modality: PROTEIN_REPLACEMENT
  target_mechanisms:
  - target: Deficient Plasmacytoid Dendritic Cell Type I Interferon Production
    description: >-
      Supplies the cytokine the patient's pDCs cannot make. The target is the production
      node rather than any downstream node because the receptor and JAK-STAT machinery
      are not affected by this lesion, so delivered interferon should still be sensed.
    evidence:
    - reference: PMID:34367187
      reference_title: Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "Although no data is yet available to support specific management of TLR7 deficiency or the at-risk hemizygous carriers, early hospitalization and IFN-based therapies in inborn errors of IFN signaling form rational treatment options"
      explanation: >-
        The source states the rationale and, in the same sentence, that no supporting
        data exist - which is why this is graded INDIRECT and the treatment described as
        unproven.
  evidence:
  - reference: PMID:34367187
    reference_title: Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Strong host genetic factors that confer an increased risk to develop severe COVID-19 might serve as genomic biomarkers, along with other factors, that could be used for early diagnosis and preventative measures, and could allow the identification of possible molecular targets for treatment."
    explanation: >-
      The general argument for genotype-directed therapy in this setting. Graded
      INDIRECT because it states a programme rather than a result in treated patients.
  - reference: PMID:36780676
    reference_title: Early Treatment with Pegylated Interferon Lambda for Covid-19.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 25 of 931 patients (2.7%) in the interferon group had a primary-outcome event, as compared with 57 of 1018 (5.6%) in the placebo group, a difference of 51% (relative risk, 0.49; 95% Bayesian credible interval, 0.30 to 0.76; posterior probability of superiority to placebo, >99.9%)."
    explanation: >-
      The only randomised result showing that giving exogenous interferon early changes
      COVID-19 outcome. INDIRECT and double-qualified: the trial enrolled
      genotype-unselected outpatients, so it does not test this disorder, and the
      interferon was type III rather than type I.
  - reference: PMID:36780676
    reference_title: Early Treatment with Pegylated Interferon Lambda for Covid-19.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among patients with a high viral load at baseline, those who received pegylated interferon lambda had lower viral loads by day 7 than those who received placebo."
    explanation: >-
      Shows the intervention acting on viral load, which is the step this treatment's
      target_mechanisms link asserts it acts on. Still INDIRECT for the reasons above.
  - reference: PMID:40818744
    reference_title: "Peginterferon λ for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trial."
    supports: REFUTE
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this phase II, prematurely stopped randomized placebo-controlled trial of peginterferon λ for individuals hospitalized with COVID-19 infection, no apparent benefit was identified."
    explanation: >-
      Refutes the late-administration form of this strategy, which is the form a
      TLR7-deficient patient diagnosed during critical illness would receive. Recorded
      as REFUTE rather than omitted because it is the main argument against the
      treatment as actually deliverable in this disorder. The trial stopped early and
      enrolled 97 participants, so it is underpowered as well as genotype-unselected.
  notes: >-
    No interferon product is established for this indication, and neither bound agent has
    been reported in a TLR7-deficient patient. NCIT:C495 Recombinant Interferon Beta is
    bound because interferon-beta is the type I subtype the cited TLR7-specific rationale
    appeals to; NCIT:C166435 Peginterferon Lambda-1A is bound because it is the agent in
    the two randomised trials cited above. Binding both, rather than one, is deliberate:
    the mechanistic argument in this disorder is for type I replacement while the trial
    evidence is for a type III agent, and collapsing that onto a single agent would hide
    the gap.
environmental:
- name: SARS-CoV-2 infection
  description: >-
    Not a modifier of this disease but a constituent of it. The genotype produces no
    phenotype in its absence: the patients were previously well, had no history of
    severe viral illness, and in the index families COVID-19 segregated as an X-linked
    recessive trait conditioned on exposure to the virus. This is why the MONDO concept
    names the infection, and why the hemizygous relatives identified by screening were
    asymptomatic rather than undiagnosed.
  exposure_term:
    preferred_term: exposure to severe acute respiratory syndrome coronavirus 2
  influences_mechanisms:
  - target: Unrestrained Early SARS-CoV-2 Replication in the Respiratory Tract
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      The virus is the ligand the receptor cannot sense and the pathogen the interferon
      response cannot contain, so the exposure initiates the mechanism rather than
      aggravating a process already under way.
    evidence:
    - reference: PMID:33650967
      reference_title: "Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Recently, loss-of-function variants in TLR7 were identified in two families in which COVID-19 segregates like an X-linked recessive disorder environmentally conditioned by SARS-CoV-2."
      explanation: >-
        States the gene-environment structure this link encodes: a Mendelian trait whose
        expression is conditional on the viral exposure.
  review_notes: >-
    ECTO was searched for an exposure class covering SARS-CoV-2 or coronavirus
    infection. The committed cache/ecto/terms.csv was searched with
    grep -i -E "sars|corona|covid|virus" cache/ecto/terms.csv, which returns no row
    matching sars, corona or covid and exactly two virus rows, ECTO:3000001 "exposure
    to virus" and ECTO:2000053 "exposure to Human Papillomavirus Infection"; the OLS
    ECTO search for "SARS-CoV-2" and for "coronavirus" returns no exposure class for
    either, while the OLS search for "virus" returns ECTO:3000001 with virus-specific
    descendants for other pathogens (Zika, yellow fever, hepatitis B and C, HIV-1) but
    none for a coronavirus. ECTO:3000001 was considered and rejected on positive
    grounds rather than on
    absence: binding "exposure to virus" to the one exposure that defines this disease
    would assert a generic viral exposure where the entry's whole content is that
    susceptibility is virus-specific and demonstrably does not extend to other viruses.
    The preferred_term is left free-text.
  evidence:
  - reference: PMID:34413140
    reference_title: "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The phenotypes of five hemizygous relatives of index cases infected with SARS-CoV-2 include asymptomatic or mild infection (n=2, 5 and 38 years), or moderate (n=1, 5 years), severe (n=1, 27 years), or critical (n=1, 29 years) pneumonia."
    explanation: >-
      The exposure-conditioned phenotype distribution among carriers, which is what
      establishes infection as the trigger and shows the penetrance is incomplete.
animal_models:
- name: Tlr7-null mouse challenged with mouse-adapted SARS-CoV-2
  species: Mouse
  genotype: Tlr7 knockout (TLR7-/-)
  publication: PMID:40162785
  description: >-
    The model that supplies what human studies cannot: direct measurement of lung viral
    load, lung interferon output and lung histology under a controlled challenge.
    TLR7-null mice infected with mouse-adapted SARS-CoV-2 have higher lung virus titres,
    lower type I and III interferon and interferon-stimulated gene expression, more
    neutrophil infiltration, worse lung pathology and higher mortality than controls.
  modeled_mechanisms:
  - target: Unrestrained Early SARS-CoV-2 Replication in the Respiratory Tract
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: TISSUE
    description: >-
      Reproduces the failure of viral control in the lung that the human disease infers
      from its interferon defect and clinical outcome.
    limitations: >-
      The challenge is a mouse-adapted virus, not the human pathogen, and the mouse
      lesion is a whole-animal knockout rather than one of the graded human alleles.
      More importantly the cellular geography differs: human TLR7 deficiency acts
      through pDC-derived interferon with no epithelial contribution, since human lung
      epithelium does not express TLR7, whereas the mouse study reports reduced
      interferon-stimulated gene expression in the lung and viral antigen in bronchial
      epithelial cells.
    readouts:
    - name: Lung virus load
      target: Unrestrained Early SARS-CoV-2 Replication in the Respiratory Tract
      direction: INCREASED
      interpretation: >-
        The quantitative correlate of failed viral containment, which is the step the
        human pathograph asserts without measuring.
      evidence:
      - reference: PMID:40162785
        reference_title: Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "We showed that TLR7 deficiency significantly increased lung virus loads and morbidity/mortality"
        explanation: Reports the measurement and its direction.
  - target: Lung Neutrophil Accumulation and Immunopathology
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: TISSUE
    description: >-
      Reproduces the inflammatory lung lesion, and establishes its position downstream
      of the viral-control failure rather than as an independent process.
    limitations: >-
      Mouse neutrophil biology and the mouse-adapted virus both differ from the human
      disease, and no histological series from TLR7-deficient human lungs exists to
      compare against.
    readouts:
    - name: Lung neutrophil accumulation and histopathology
      target: Lung Neutrophil Accumulation and Immunopathology
      direction: INCREASED
      interpretation: The structural correlate of the immunopathology node in this model.
      evidence:
      - reference: PMID:40162785
        reference_title: Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "A detailed evaluation of MA-CoV-2-infected lungs revealed increased neutrophil accumulation and lung pathology in TLR7-/- mice."
        explanation: Reports the histological measurement behind this readout.
  evidence:
  - reference: PMID:40162785
    reference_title: Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Additionally, given the similar disease outcomes in control, TLR7-/-, and IFNAR-deficient MA-CoV-2-infected mice and coronavirus disease 2019 (COVID-19) patients, we propose that MA-CoV-2-infected mice constitute an excellent model for studying COVID-19."
    explanation: >-
      The authors' own claim for the model's relevance. Cited as the basis for treating
      it as informative, not as independent validation of that claim.
- name: Tlr7-null mouse with immune-cell-restricted deficiency (bone marrow chimera)
  species: Mouse
  genotype: Tlr7 knockout and Irf7 knockout, including bone marrow transplant chimeras
  publication: PMID:39289468
  description: >-
    Addresses which compartment the requirement sits in. Global and
    immune-cell-restricted Tlr7 or Irf7 deficiency both worsen murine COVID-19 through
    impaired interferon activation and higher lung viral load, and both also reduce
    anti-SARS-CoV-2 antibody production, delaying viral clearance.
  modeled_mechanisms:
  - target: Deficient Plasmacytoid Dendritic Cell Type I Interferon Production
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Reproduces the interferon-production failure and, through the chimeras, locates it
      in the immune compartment - the compartment the human disease implicates.
    limitations: >-
      The model does not isolate pDCs, which is the specific cell the human disorder
      turns on; it reports the immune compartment as a whole and additionally implicates
      non-immune cells, which the human lesion cannot involve because human lung
      epithelium does not express TLR7. The study also pairs Tlr7 with Irf7, a gene
      acting downstream of several sensors, so not every reported effect is attributable
      to TLR7.
    readouts:
    - name: Circulating interferon alpha and gamma
      target: Deficient Plasmacytoid Dendritic Cell Type I Interferon Production
      direction: DECREASED
      interpretation: >-
        Systemic consequence of the production defect, measured in the circulation
        rather than in sorted cells.
      evidence:
      - reference: PMID:39289468
        reference_title: Deficiency of Tlr7 and Irf7 in mice increases the severity of COVID-19 through the reduced interferon production.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "These effects are associated with reduced IFN alpha and gamma levels in the circulation."
        explanation: Reports the measured direction of both interferon arms in the model.
  evidence:
  - reference: PMID:39289468
    reference_title: Deficiency of Tlr7 and Irf7 in mice increases the severity of COVID-19 through the reduced interferon production.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We demonstrate that at the early phase of infection, SARS-CoV-2 causes the upregulation of Tlr7, Irf7, and IFN pathways in the lungs of the infected mice."
    explanation: >-
      Establishes that the pathway is engaged early in infection in this model, which is
      the premise for using its knockout as a model of the human timing.
discussions:
- discussion_id: tlr7_b_cell_antibody_species_mismatch
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Does B-cell-intrinsic TLR7 signalling contribute to the antibody response against
    SARS-CoV-2 in humans, as it does in mice, or is the human humoral response
    TLR7-independent?
  attaches_to:
  - pathophysiology#Defective B Cell and Myeloid TLR7 Responsiveness
  rationale: >-
    The two species give opposite answers, and both results are direct. In mice,
    Tlr7 deficiency abolishes germinal-centre-dependent class-switched IgG2b/IgG2c and
    neutralising antibody to SARS-CoV-2, and a B-cell-intrinsic requirement is
    demonstrated; a second murine study independently reports substantially reduced
    anti-SARS-CoV-2 antibody with delayed viral clearance. In TLR7-deficient humans
    given an mRNA vaccine, the RBD-specific memory B cell response is quantitatively
    and qualitatively similar to healthy donors and neutralising IgG is largely
    unaffected for seven months. The mismatch is mechanistically meaningful rather
    than a technical discrepancy: the human data are from a nucleoside-modified mRNA
    vaccine designed not to engage innate RNA sensors, whereas the murine data use
    inactivated virus and a pathogen-like particle carrying bacterial single-stranded
    RNA as a deliberate TLR7 ligand. So the comparison may be between two different
    antigens rather than between two species. It matters clinically: if the human B
    cell compartment does need TLR7 for a response to the virus itself, the normal
    mRNA-vaccine response does not license the conclusion that convalescent immunity
    in these patients is intact, and the entry's main intervention rests on that
    conclusion.
  proposed_experiments:
  - experiment_id: tlr7_natural_infection_antibody_response
    name: Natural-infection antibody response in TLR7-deficient patients versus relatives
    description: >-
      Measure RBD-specific class-switched IgG, memory B cell frequency and serum
      neutralising titre after natural SARS-CoV-2 infection (not vaccination) in
      TLR7-deficient patients, their non-carrier relatives and heterozygous mothers.
      Natural infection presents unmodified viral single-stranded RNA, which is the
      ligand the modified mRNA vaccine was engineered to avoid, so this is the
      comparison that separates a species difference from an antigen difference.
    would_support:
    - pathophysiology#Defective B Cell and Myeloid TLR7 Responsiveness
    supporting_outcome:
    - >-
      Reduced class-switched RBD-specific IgG and neutralising titre in TLR7-deficient
      patients relative to infected non-carrier relatives, with preserved responses to
      mRNA vaccination in the same individuals.
    would_refute:
    - pathophysiology#Defective B Cell and Myeloid TLR7 Responsiveness
    refuting_outcome:
    - >-
      Class-switched RBD-specific IgG, memory B cell frequency and neutralising titre
      after natural infection indistinguishable from infected non-carrier relatives,
      which would confine the B cell defect to the in vitro stimulation phenotype.
  evidence:
  - reference: PMID:37438976
    reference_title: B cell-intrinsic TLR7 signaling is required for neutralizing antibody responses to SARS-CoV-2 and pathogen-like COVID-19 vaccines.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Upon repeated immunization with inactivated SARS-CoV2 or PLA COVID-19 vaccine, we show that Tlr7-deficiency abolished the germinal center (GC)-dependent production of RBD-specific class-switched IgG2b and IgG2c, and neutralizing antibodies to SARS-CoV2."
    explanation: The murine side of the mismatch, including the B-cell-intrinsic requirement.
  - reference: PMID:39289468
    reference_title: Deficiency of Tlr7 and Irf7 in mice increases the severity of COVID-19 through the reduced interferon production.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Despite higher amounts of lung viral antigen, Tlr7 or Irf7 deficiency resulted in substantially reduced production of antibodies against SARS-CoV-2, thereby delaying the viral clearance."
    explanation: >-
      Independent murine replication of the antibody defect, with the additional
      observation that it delays viral clearance.
  - reference: PMID:36342455
    reference_title: Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Sustained germinal center responses led to accumulation of somatic hypermutations in immunoglobulin heavy chain genes."
    explanation: >-
      The human side: the germinal-centre step that fails in Tlr7-null mice proceeds in
      TLR7-deficient patients.
- discussion_id: tlr7_propofol_sedation_interaction
  kind: INTERPRETATION
  status: OPEN
  prompt: >-
    Does propofol sedation further suppress TLR7 signalling in a patient whose residual
    TLR7 function is already reduced, and should sedation choice differ in a
    TLR7-hypomorphic patient being ventilated for COVID-19?
  attaches_to:
  - pathophysiology#Abolished MyD88-Dependent Signal Transduction
  - treatments#Early exogenous interferon therapy
  rationale: >-
    Propofol binds TLR7 directly and hinders its association with MyD88, attenuating
    interferon induction in dendritic cells and in lung tissue. The pharmacological
    target is precisely this entry's signalling node, and the clinical setting in which
    these patients are identified is one in which propofol is routinely given: they are
    diagnosed while intubated for critical COVID-19 pneumonia. For an outright
    loss-of-function allele the question does not arise, since there is no signal left
    to inhibit. It arises for the hypomorphic and hypofunctional alleles, which retain
    measurable activity and account for several of the reported patients, and for
    heterozygous female carriers. This is recorded as an interpretation rather than as a
    treatment caution because the evidence is biochemical and murine: no study has
    measured interferon output in a TLR7-hypomorphic patient under propofol, and no
    clinical comparison against another sedative exists.
  evidence:
  - reference: PMID:35899460
    reference_title: Propofol directly binds to and inhibits TLR7.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We also found that propofol directly bound to and hindered its association of TLR7 with MyD88."
    explanation: >-
      The molecular interaction, at exactly the receptor-to-adaptor step this entry's
      pathophysiology node describes.
  - reference: PMID:35899460
    reference_title: Propofol directly binds to and inhibits TLR7.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "R837 increased IFN-β expression in the lungs, and propofol attenuated IFN-β expression in an in vivo model of R837 intranasal instillation."
    explanation: >-
      Shows the interaction reducing interferon output in lung tissue in vivo, which is
      the organ and the output that matter here. INDIRECT because it is a murine
      agonist-challenge model, not a patient.
- discussion_id: tlr7_neurological_sequelae
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Does TLR7 deficiency contribute to neurological deterioration after COVID-19, or is
    the single reported case a coincidence of two findings in one patient?
  attaches_to:
  - phenotypes#Severe viral infection
  rationale: >-
    One pediatric patient with post-COVID-19 neurological deterioration was found to
    carry a novel hemizygous frameshift TLR7 allele, and the reporting authors suggest
    TLR7 loss of function may contribute to neurological complications. That is a single
    case, the authors themselves hedge it, and no neurological phenotype appears in any
    of the cohort studies - so no neurological phenotype is curated in this entry. The
    gap is recorded rather than resolved because the cohorts were assembled on
    respiratory severity and would not have detected a neurological outcome had one
    existed. A second patient in whom TLR7 deficiency coexisted with
    ataxia-telangiectasia shows the shape of the confound: that patient's neurological
    signs were attributable to a homozygous ATM variant, with TLR7 accounting only for
    the COVID-19 severity.
  evidence:
  - reference: PMID:38093758
    reference_title: "Novel TLR7 hemizygous variant in post-COVID-19 neurological deterioration: a case report with literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, our preliminary findings also suggest TLR7 loss of function may contribute to neurological complications post-COVID-19, especially in young previously healthy patients."
    explanation: >-
      The hypothesis, in the authors' own hedged terms, and the whole of the evidence
      for it.
  - reference: PMID:34686943
    reference_title: X-Linked TLR7 Deficiency Underlies Critical COVID-19 Pneumonia in a Male Patient with Ataxia-Telangiectasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report a unique IEI patient with combined ATM and TLR7 deficiencies. The two genetic defects underlie A-T and critical COVID-19 in this patient, respectively."
    explanation: >-
      The worked example of attributing neurological disease to the other gene and
      COVID-19 severity to TLR7 - the confound this gap is about.
notes: >-
  Scope. This entry curates the Mendelian disorder: hemizygous deleterious TLR7 alleles
  causing severe or critical COVID-19 in males. The large common-variant literature on
  TLR7 polymorphisms (rs179008, rs179009, rs3853839) and COVID-19 severity is a
  susceptibility question at the same locus, not this disease, and is recorded only as a
  caveat on the genetic record. The MONDO concept itself is the Mendelian one, carrying
  OMIM 301051 as an exact match.

  Why the phenotype list is short and respiratory. The cohorts that define this disorder
  were assembled on COVID-19 severity, so the phenotype spectrum is what those cohorts
  measured. No immunological laboratory phenotype is curated even though the interferon
  defects are well documented, because what is measured in the patients is a stimulated
  response in isolated cells rather than a circulating analyte concentration. HPO's
  nearest terms (HP:0011116 Abnormal circulating interferon concentration, read from
  the OLS HP search, and HP:0034513 Increased circulating Interferon-alpha
  concentration, read from cache/hp/terms.csv) describe a circulating concentration, so
  binding either to an ex vivo stimulation assay would misdescribe the measurement.
  Those findings are carried as pathophysiology nodes with their own evidence instead,
  and no biochemical block is curated for the same reason.

  Phenotype frequencies are deliberately absent. Every cohort here was ascertained on
  COVID-19 severity, so the proportion of patients with pneumonia or hypoxaemia is a
  property of the selection rather than of the genotype, and the only honest frequency
  figures are the diagnostic yields recorded under prevalence.
review_notes: >-
  Deep research. One openscientist deep-research report was commissioned for this entry
  (`just research-disorder openscientist Immunodeficiency_74_COVID-19-related_X-linked`),
  and is committed alongside it. The report's disease identity was checked by hand against
  the MONDO record: it names TLR7, Xp22.2 and OMIM 301051, which is the OMIM number
  MONDO:0026767 carries as an exact match, so there is no named-entity confusion. That
  identity check was done by hand because `just preflight-dr` needs the local MONDO
  build, which was not available.

  Four of the report's leads were followed up, independently verified against the fetched
  abstracts, and are curated: the 21-cohort exome-wide burden estimate (PMID:36327219),
  the escape of TLR7 from X-inactivation as the reason heterozygous women are buffered
  (PMID:38481993), the two randomised peginterferon-lambda trials that between them show
  interferon benefit is confined to an early window (PMID:36780676, PMID:40818744), and
  the direct inhibition of TLR7-MyD88 association by propofol (PMID:35899460). None of
  these came out of the cohort literature this entry was otherwise built from.

  Two leads were read and not used. PMID:41961811, offered in support of pDC interferon
  output as a functional biomarker and of visceral adiposity as a non-genetic modifier, is
  a real paper on that subject but concerns neither this genotype nor this disease, so
  citing it here would import an association from a different population. The report's
  bidirectional framing of TLR7 - that enhanced rather than absent TLR7-driven interferon
  production underlies pandemic chilblains (PMID:40227192) - checks out against that
  paper's own title and abstract, but it is a different disease and belongs in its own
  entry rather than as background in this one.

  No CURIE in this entry comes from the report. The bindings were resolved against the
  OLS REST search (HP, GO, CL, NCIT) and the committed cache CSVs (HGNC, NCIT, CL, GO).

  Module conformance. Two nodes conform to `innate_antiviral_interferon_response`:
  the sensing failure to its PAMP-sensing node, and the pDC interferon node to its
  `Type I and III Interferon Induction and JAK-STAT Signaling` node. The second is a
  partial fit and the node's description says how: the module node bundles induction
  with JAK-STAT signalling, and this lesion loses only induction. No other module node
  matches - the ISG-antiviral-state and viral-antagonism nodes describe steps that are
  intact here, and the restriction-of-replication node is the module's protective
  output rather than this entry's failure of it.

  Standard severe-COVID care is out of scope. Early direct-acting antivirals and the
  late-phase immunomodulators (dexamethasone, IL-6 blockade, JAK inhibitors) are given
  to these patients as they are to any critical COVID-19 patient, and no study reports
  either in a TLR7-deficient cohort, so they would be genotype-unselected standard care
  recorded as though it were disease-specific. The one genotype-unselected intervention
  that is curated, exogenous interferon, is there because the mechanistic argument for
  it is specific to this lesion and is made explicitly in this disorder's own
  literature.

  Not curated, and why. The discovery cohort's 16 TLR7-deficient patients were all
  tested for neutralising autoantibodies against type I interferon and all negative.
  That is a property of how the cohort was selected - patients with such autoantibodies
  were excluded before the TLR7 analysis - rather than a feature of the disease, so it
  is not curated as one.

📚

References & Deep Research

References

3

PMID:34413140

X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19.

No top-level findings curated for this source.

PMID:32706371

Presence of Genetic Variants Among Young Men With Severe COVID-19.

No top-level findings curated for this source.

PMID:35748970

Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Record review notes

Deep research. One openscientist deep-research report was commissioned for this entry (`just research-disorder openscientist Immunodeficiency_74_COVID-19-related_X-linked`), and is committed alongside it. The report's disease identity was checked by hand against the MONDO record: it names TLR7, Xp22.2 and OMIM 301051, which is the OMIM number MONDO:0026767 carries as an exact match, so there is no named-entity confusion. That identity check was done by hand because `just preflight-dr` needs the local MONDO build, which was not available. Four of the report's leads were followed up, independently verified against the fetched abstracts, and are curated: the 21-cohort exome-wide burden estimate (PMID:36327219), the escape of TLR7 from X-inactivation as the reason heterozygous women are buffered (PMID:38481993), the two randomised peginterferon-lambda trials that between them show interferon benefit is confined to an early window (PMID:36780676, PMID:40818744), and the direct inhibition of TLR7-MyD88 association by propofol (PMID:35899460). None of these came out of the cohort literature this entry was otherwise built from. Two leads were read and not used. PMID:41961811, offered in support of pDC interferon output as a functional biomarker and of visceral adiposity as a non-genetic modifier, is a real paper on that subject but concerns neither this genotype nor this disease, so citing it here would import an association from a different population. The report's bidirectional framing of TLR7 - that enhanced rather than absent TLR7-driven interferon production underlies pandemic chilblains (PMID:40227192) - checks out against that paper's own title and abstract, but it is a different disease and belongs in its own entry rather than as background in this one. No CURIE in this entry comes from the report. The bindings were resolved against the OLS REST search (HP, GO, CL, NCIT) and the committed cache CSVs (HGNC, NCIT, CL, GO). Module conformance. Two nodes conform to `innate_antiviral_interferon_response`: the sensing failure to its PAMP-sensing node, and the pDC interferon node to its `Type I and III Interferon Induction and JAK-STAT Signaling` node. The second is a partial fit and the node's description says how: the module node bundles induction with JAK-STAT signalling, and this lesion loses only induction. No other module node matches - the ISG-antiviral-state and viral-antagonism nodes describe steps that are intact here, and the restriction-of-replication node is the module's protective output rather than this entry's failure of it. Standard severe-COVID care is out of scope. Early direct-acting antivirals and the late-phase immunomodulators (dexamethasone, IL-6 blockade, JAK inhibitors) are given to these patients as they are to any critical COVID-19 patient, and no study reports either in a TLR7-deficient cohort, so they would be genotype-unselected standard care recorded as though it were disease-specific. The one genotype-unselected intervention that is curated, exogenous interferon, is there because the mechanistic argument for it is specific to this lesion and is made explicitly in this disorder's own literature. Not curated, and why. The discovery cohort's 16 TLR7-deficient patients were all tested for neutralising autoantibodies against type I interferon and all negative. That is a property of how the cohort was selected - patients with such autoantibodies were excluded before the TLR7 analysis - rather than a feature of the disease, so it is not curated as one.

Create: Immunodeficiency_74_COVID-19-related_X-linked · 2026-10-01T20:58:06Z · View source

De novo creation of the X-linked recessive TLR7 deficiency (IMD74, MONDO:0026767) entry, curated as a Disease rather than a GROUPING or SUBTYPE: MONDO:0026767 is a leaf under immunodeficiency disease with a single causal gene (TLR7, hgnc:15631), one OMIM exact match (301051), and no descendants, and the disorder is a named clinical entity in the IUIS 2022 inborn-errors-of-immunity classification. Pathograph. Nine pathophysiology nodes forming one chain from the molecular lesion to the clinical endpoint: TLR7 Loss of Function -> Failure of Endosomal Single-Stranded RNA Sensing -> Abolished MyD88-Dependent Signal Transduction, branching to Deficient Plasmacytoid Dendritic Cell Type I Interferon Production, Impaired Type II Interferon Induction and Defective B Cell and Myeloid TLR7 Responsiveness, then Unrestrained Early SARS-CoV-2 Replication in the Respiratory Tract -> Lung Neutrophil Accumulation and Immunopathology and -> Hypoxemic COVID-19 Pneumonia, which wires through to all five phenotypes by bare-name targets. All five phenotype nodes are causally connected (just list-disconnected-phenotypes reports 5/5). The disease-defining exposure is modelled as an environmental entry linked with environmental_effect TRIGGERS, since the genotype is clinically silent until SARS-CoV-2 infection. Deep research. Exactly one openscientist deep-research report was commissioned and is committed with the entry, together with its citations sidecar and its two-file artifacts directory. just preflight-dr could not run: it exits 2 because the local MONDO build is absent and the recipe refuses to download it implicitly, so disease identity was checked by hand instead (the report names TLR7, Xp22.2 and OMIM 301051, matching the MONDO record's exact match). The report carried no Term Validation or reference-validation section despite the recipe passing --validate-terms and --validate-references, so every CURIE in this entry was resolved independently by lookup and none was taken from the report. Four of its leads were verified against the fetched abstracts and curated: the 21-cohort exome-wide burden estimate (PMID:36327219), TLR7 escape from X-inactivation as the buffer in heterozygous women (PMID:38481993), the paired early-outpatient and late-inpatient peginterferon-lambda trials (PMID:36780676, PMID:40818744), and the direct propofol inhibition of TLR7-MyD88 association (PMID:35899460), which is recorded as an INTERPRETATION discussion rather than a treatment caution because the evidence is biochemical and murine. Two leads were read and rejected, with the reasons recorded in the entry's review_notes. Evidence. 82 evidence snippets across 22 cited references, all exact-quote verified against references_cache (82/82). Two REFUTE items are deliberate: the normal human mRNA-vaccine B cell response against the B cell node, and the negative late-administration interferon trial against the interferon treatment. One HUMAN_MODEL_MISMATCH discussion records the opposite answers mouse and human give on whether B-cell-intrinsic TLR7 is needed for anti-SARS-CoV-2 antibody, with a proposed natural-infection experiment; one KNOWLEDGE_GAP records the single-case neurological-sequelae question and the ataxia-telangiectasia confound. Two unbound terms are recorded with the searches that justify them: no ECTO class exists for SARS-CoV-2 exposure (ECTO:9000018 exposure to virus was rejected on positive grounds, since this disorder's susceptibility is virus-specific), and no NCIT clinical-action term exists for the luciferase signalling assay. No biochemical block and no phenotype frequencies are curated, for reasons stated in notes: the interferon findings are ex vivo stimulated responses rather than circulating analyte concentrations, and every cohort was ascertained on COVID-19 severity. Validation. just validate, count-verified-snippets (82/82), validate-terms, check-entity-refs, check-causal-targets, check-duplicate-keys, check-qualifier-terms, check-snippet-length, check-title-snippets, check-snippet-grading, check-environmental-evidence, check-folded-hyphens, check-coarse-phenotypes, check-case-collisions, check-enum-values, check-genereviews (no GeneReviews or StatPearls chapter exists for this disorder in the committed Bookshelf index) and the batched just validate-disorders all pass. just normalize-cache added ten additive rows across eight cache files. The stub is deleted in the same commit.

OpenScientist ▸

Immunodeficiency 74, COVID-19-Related, X-Linked (IMD74): Comprehensive Disease Characterization Report

openscientist-autonomous 23 citations 2026-10-01T20:27:55.874212

Immunodeficiency 74, COVID-19-Related, X-Linked (IMD74): Comprehensive Disease Characterization Report

MONDO ID: MONDO:0026767 | OMIM: #301051 | Gene: TLR7 (Xp22.2) | Category: Mendelian (X-linked recessive, infection-conditional)

Summary

Immunodeficiency 74, COVID-19-related, X-linked (IMD74) is a Mendelian inborn error of immunity in which hemizygous loss-of-function (LOF) variants in TLR7 (Toll-like receptor 7, located at Xp22.2) predispose otherwise healthy males to life-threatening, hypoxemic COVID-19 pneumonia. It is a disease defined by the intersection of a rare monogenic susceptibility and an obligate environmental trigger — infection with SARS-CoV-2. In the absence of the virus, affected individuals are generally healthy; the "immunodeficiency" is conditional and virus-specific. IMD74 was the first monogenic cause of severe COVID-19 to be described, discovered by rapid whole-exome sequencing of young men in two unrelated Dutch families in 2020 (PMID: 32706371).

The core mechanism is a defect in innate antiviral sensing. TLR7 is an endosomal single-stranded RNA (ssRNA) sensor that, upon recognizing guanosine and uridine-containing viral RNA, signals through MyD88 and IRAK-4 to drive production of type I and type III interferons (IFNs), chiefly by plasmacytoid dendritic cells (pDCs). When TLR7 is non-functional, SARS-CoV-2 goes unsensed, the protective early interferon response fails, the virus replicates unchecked, and a delayed, dysregulated hyperinflammatory response produces severe lung injury. IMD74 therefore sits within the broader paradigm — established during the pandemic — that defective type I IFN immunity (whether genetic or caused by neutralizing autoantibodies) underlies at least 10% of critical COVID-19 pneumonia.

Quantitatively, rare deleterious TLR7 variants raise the risk of severe COVID-19 roughly 5.3-fold (95% CI 2.75–10.05; p = 5.41×10⁻⁷) in a large exome-wide burden study, and X-linked TLR7 deficiency accounts for ~1% of life-threatening COVID-19 in men under 60, with high penetrance. Disease is strongly male-predominant because TLR7 is X-linked; heterozygous female carriers are largely protected because TLR7 escapes X-inactivation and is biallelically expressed in up to 30% of female immune cells. Intriguingly, the gene is bidirectionally disease-relevant: while LOF causes severe COVID-19, TLR7 gain-of-function/hyperresponsiveness drives interferonopathy (pandemic chilblains) and systemic lupus erythematosus. The most biologically rational, and partially RCT-supported, therapeutic strategy is early exogenous interferon (type III IFN-λ given early in infection) alongside vaccination to remove the viral trigger.

Section 1 — Disease Information

Overview. IMD74 is an X-linked recessive, SARS-CoV-2–conditional inborn error of immunity. Affected hemizygous males carry loss-of-function variants in TLR7 and are predisposed to severe/critical COVID-19 (hypoxemic pneumonia frequently requiring high-flow oxygen, mechanical ventilation, or ICU admission), typically despite being young and free of major comorbidities. It is a "disease" only in the context of infection — the genetic lesion is clinically silent until SARS-CoV-2 exposure.

Key identifiers.

Resource	Identifier
OMIM	#301051 (Immunodeficiency 74, COVID19-related, X-linked; IMD74)
MONDO	MONDO:0026767
Gene	TLR7, HGNC, Xp22.2
MeSH (related)	COVID-19; Toll-Like Receptor 7; Primary Immunodeficiency Diseases
ICD-10	U07.1 (COVID-19) + D84.x (other specified immunodeficiencies) — no dedicated code
ICD-11	RA01.0 (COVID-19, virus identified) + 4A00.x immunodeficiency — no dedicated code

Synonyms / alternative names. Immunodeficiency 74, COVID-19-related, X-linked; IMD74; X-linked TLR7 deficiency; X-linked recessive TLR7 deficiency; TLR7-deficiency-associated severe COVID-19.

Source of information. Evidence is derived from a mixture of individual patient data (family-based WES, case series, functional studies on patient cells) and aggregated disease-level resources (OMIM, large multi-cohort genetic burden studies such as the COVID-19 Host Genetics Initiative). The founding studies were individual-patient (EHR + genomic), subsequently generalized by population-scale analyses.

Section 2 — Etiology

Disease causal factors. IMD74 is caused by the combination of (1) a germline genetic lesion — hemizygous LOF variants in TLR7 — and (2) an infectious trigger — SARS-CoV-2. Neither alone produces the disease. This is a canonical gene–environment (gene–pathogen) interaction: the monogenic defect determines who, among the infected, progresses to life-threatening disease.

Genetic risk factors. The causal locus is TLR7 (Xp22.2). Rare LOF and hypomorphic missense variants are the drivers. The founding Dutch families carried rare putative LOF variants segregating with severe disease (PMID: 32706371). In the Italian GEN-COVID nested case-control cohort, deleterious TLR7 variants were found in 2.1% of severely affected males and 0% of asymptomatic participants (PMID: 33650967). The exome-wide burden estimate is a 5.3-fold increase in severe disease per rare deleterious TLR7 variant (PMID: 36327219).

Environmental risk factors. The obligate environmental factor is SARS-CoV-2 infection. Male sex is a strong risk modifier (hemizygosity; androgen suppression of pDC IFN-I). Age <60 is the window in which the monogenic contribution is proportionally largest (since in older patients comorbidity and other factors dominate). Broader non-genetic factors that blunt pDC IFN-I (e.g., visceral adiposity) are associated with SARS-CoV-2 infection history (PMID: 41961811), providing a converging physiological axis.

Protective factors. Genetic: carriage of a functional TLR7 allele; in females, biallelic TLR7 expression due to escape from X-inactivation is protective. Mechanistic/physiological: TLR7 hyperresponsiveness (the opposite of IMD74) confers pDC-mediated near-sterilizing protection against SARS-CoV-2, at the cost of IFN-driven chilblains (PMID: 40227192). Vaccination and functional type I IFN immunity are protective.

Gene–environment interactions. IMD74 is essentially a textbook GxE disorder: the penetrant phenotype emerges only when a TLR7-deficient host encounters SARS-CoV-2. The same genotype would be expected to raise risk for other TLR7-sensed ssRNA viruses, though the strongest evidence is for SARS-CoV-2.

Section 3 — Phenotypes

The principal phenotype is severe/critical COVID-19 in a young, otherwise healthy male. Component phenotypes:

Phenotype	Type	Suggested HPO	Onset	Severity	Frequency in affected
Severe viral pneumonia / hypoxemic respiratory failure	Clinical sign	HP:0002090 (Pneumonia), HP:0012418 (Hypoxemia)	Adult (conditional on infection)	Severe	Defining feature
Acute respiratory distress syndrome (ARDS)	Clinical sign	HP:0033677 (ARDS)	Acute	Severe	Common in ICU cases
Susceptibility to viral infection (SARS-CoV-2)	Laboratory/clinical	HP:0002718 (Recurrent bacterial/viral infections)	Conditional	Variable	Defining
Impaired type I interferon response	Laboratory abnormality	HP:0002721 (Immunodeficiency)	—	—	Essentially all
Fever	Symptom	HP:0001945	Acute	Moderate–severe	Common
Lymphopenia	Laboratory abnormality	HP:0001888	Acute	Variable	Common in severe COVID-19

Phenotype characteristics. Onset: adult-conditional — the phenotype appears only upon SARS-CoV-2 infection, typically in men under 60 (first cases: mean age 26 years, PMID: 32706371). Severity: severe to critical by definition of the ascertained phenotype, though the underlying genotype can also associate with milder disease in some carriers (variable expressivity). Progression: acute and often rapid, following the natural history of severe COVID-19 — a self-limited (resolving or fatal) episode rather than a chronic condition. Frequency: among men under 60 with life-threatening COVID-19, ~1% are explained by X-linked TLR7 deficiency (PMID: 34413140); described as high penetrance for hypoxemic pneumonia (PMID: 36880831).

Quality of life impact. During the acute episode, QoL impact is profound (ICU stay, mechanical ventilation, ECMO in severe cases). Survivors may experience post-ICU and post-COVID sequelae. Between infections, carriers are generally healthy, so chronic QoL burden is low outside infectious episodes.

Section 4 — Genetic / Molecular Information

Causal gene. TLR7 (Toll-like receptor 7), Xp22.2; encodes an endosomal pattern-recognition receptor. OMIM gene/phenotype #301051.

Pathogenic variants. - Affected gene: TLR7 (HGNC: TLR7). UniProt Q9NYK1. - Variant classification: Rare, biochemically deleterious variants classified as pathogenic/likely pathogenic when functional assays confirm LOF; some are hypomorphic/hypofunctional. Functional validation (luciferase reporter assays, transcriptomic response to agonist) is central to classification because many are private missense variants of otherwise uncertain significance. - Variant types: Predominantly missense (e.g., N215S classified as LOF; D332G as hypomorphic in the Spanish cohort, PMID: 40423910), as well as frameshift/nonsense putative LOF variants in the founding families (PMID: 32706371). - Allele frequency: Very rare in gnomAD (private or ultra-rare), consistent with strong effect sizes. - Origin: Germline, hemizygous in affected males. - Functional consequence: Loss of function — impaired ssRNA sensing and failure to induce interferon. This contrasts with the gain-of-function end of the TLR7 allelic spectrum seen in lupus/interferonopathy.

Functional demonstration. RNA-seq of patient PBMCs after stimulation with the TLR7 agonist imiquimod showed profound pathway impairment, with reduced induction of IFNA, IFNG, RSAD2, ACOD1, IFIT2, and CXCL10; hypomorphic variants failed to upregulate IFN-γ (PMID: 34952932).

Modifier genes. Components of the TLR7 signaling axis (MyD88, IRAK4) are themselves monogenic determinants of hypoxemic COVID-19 (PMID: 36880831), and would be expected to modify or phenocopy the defect. Downstream IFN-pathway genes and autoantibody status (anti–type I IFN) are convergent modifiers of the same end phenotype.

Epigenetic information. The most important epigenetic feature is escape from X-chromosome inactivation: TLR7 is biallelically expressed in up to 30% of female immune cells (PMID: 38481993), which protects heterozygous female carriers. No skewed X-inactivation was observed in female carriers of N215S or D332G (PMID: 40423910).

Chromosomal abnormalities. None characteristic; IMD74 is a single-gene disorder, not a structural/aneuploidy syndrome.

Section 5 — Environmental Information

Infectious agent (the defining environmental factor). SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2; NCBI Taxonomy taxid 2697049; genus Betacoronavirus). SARS-CoV-2 is a positive-sense ssRNA virus; its genomic/replicative ssRNA (with uridine/guanosine motifs) is the natural TLR7 ligand. Without this trigger the genotype is clinically silent.

Environmental/physiological modifiers. Androgens suppress pDC IFN-I production (PMID: 38481993); visceral fat obesity is associated with lower pDC-derived IFN-α and with history of SARS-CoV-2 infection (PMID: 41961811). Propofol directly binds TLR7 and inhibits its association with MyD88, attenuating IFN production — a potential iatrogenic environmental modifier in sedated/ventilated patients (PMID: 35899460).

Lifestyle factors. No specific lifestyle factor causes IMD74; general determinants of COVID-19 severity apply. Vaccination is the principal modifiable protective exposure.

Section 6 — Mechanism / Pathophysiology

Ordered causal chain

A hemizygous loss-of-function variant in TLR7 (Xp22.2) results in a non-functional or hypofunctional TLR7 endosomal receptor in a male host.
Upon SARS-CoV-2 infection, viral ssRNA (guanosine- and uridine-containing) enters the endosome but the defective TLR7 fails to recognize it — loss of dual-ligand sensing at the m-shaped homodimer's two ligand-binding sites (PMID: 27742543).
Failed sensing leads to absent/blunted MyD88– and IRAK-4–dependent downstream signaling (PMID: 36880831).
This results in failure of plasmacytoid dendritic cells to produce type I (and type III) interferons — demonstrated as impaired induction of IFNA, IFNG, RSAD2, IFIT2, CXCL10 on agonist challenge (PMID: 34952932).
Absent early interferon leads to uncontrolled SARS-CoV-2 replication in the respiratory tract (inferred from the IFN-deficiency paradigm; viral kinetics not directly measured in all TLR7 patients).
Unchecked viral spread to the lungs results in a delayed, dysregulated hyperinflammatory response — a late IFN/cytokine surge, macrophage activation, and tissue injury (branch point: pDC-primed macrophage cytokine storm, PMID: 36083891).
The net result is hypoxemic COVID-19 pneumonia / ARDS requiring intensive support, with high penetrance (PMID: 36880831).

Branch (protective mirror): at the opposite end of the TLR7 dosage spectrum, TLR7 hyperresponsiveness produces abnormally high early IFN-I on sensing SARS-CoV-2 ssRNA → near-sterilizing pDC-mediated immunity → asymptomatic/mild infection, with IFN-driven chilblains as the trade-off (PMID: 40227192).

Detail by category

Molecular pathways: TLR7 → MyD88 → IRAK4/IRAK1 → IRF7 (and NF-κB) → transcription of type I/III IFNs and ISGs. GO:0002224 (toll-like receptor signaling pathway), GO:0034154 (toll-like receptor 7 signaling pathway), GO:0060337 (type I interferon signaling pathway), GO:0032481 (positive regulation of type I interferon production).
Cellular processes: innate antiviral sensing, interferon production, and downstream inflammation. Defective in pDCs; downstream, pDC-derived IFN-α normally primes macrophages — in its dysregulated form this contributes to the cytokine storm (PMID: 36083891, PMID: 37253946).
Protein dysfunction: LOF missense variants in the ectodomain leucine-rich repeats disrupt ligand binding at the structurally defined first (guanosine) and second (uridine/ssRNA) sites of the activated TLR7 dimer (PMID: 27742543).
Immune system involvement: this is a primary innate immunodeficiency of antiviral interferon immunity; it places IMD74 within the ≥10% of critical COVID-19 explained by inborn errors of type I IFN immunity and anti-IFN autoantibodies (PMID: 34413140).
Tissue damage mechanisms: delayed/exaggerated inflammation, endothelial injury, and macrophage-driven cytokine storm in the lung; late IFN surge amplifies inflammation (PMID: 40939529).
Molecular profiling: transcriptomic impairment of the TLR7/ISG program in patient cells (PMID: 34952932); single-cell/lung studies show pDC infiltration coupling to macrophage IFN signatures in severe disease (PMID: 36083891).

Cell types (CL): plasmacytoid dendritic cell (CL:0000784); macrophage (CL:0000235); monocyte-derived macrophage. Upstream vs downstream: the TLR7 lesion and failed pDC IFN-I are upstream; viral replication, late cytokine storm, and lung injury are downstream.

Section 7 — Anatomical Structures Affected

Organ level. Primary: lung (UBERON:0002048) — the site of hypoxemic pneumonia/ARDS. Secondary/systemic: multi-organ involvement via systemic inflammation (kidney failure, need for ECMO in severe cases). Body system: respiratory system (UBERON:0001004) primarily; immune/hematopoietic system functionally.

Tissue and cell level. Affected tissues: pulmonary alveolar epithelium and endothelium (site of injury); the functionally defective cells are plasmacytoid dendritic cells (CL:0000784), with downstream involvement of macrophages (CL:0000235) and monocytes. pDCs infiltrate the lung in severe COVID-19 (PMID: 36083891).

Subcellular level. The key compartment is the endosome/endolysosome (GO:0005768 endosome; GO:0010008 endosome membrane) — the location of TLR7. Signaling also engages trafficking machinery and the nucleus (IRF7-driven transcription).

Localization / lateralization. Pulmonary involvement is typically bilateral (bilateral ground-glass/consolidative pneumonia characteristic of severe COVID-19).

Section 8 — Temporal Development

Onset. The underlying genotype is congenital, but the clinical phenotype is adult-conditional and acute, triggered by SARS-CoV-2 infection. First-described cases were young men (mean 26 years) (PMID: 32706371). Onset pattern: acute, following the incubation and early-symptomatic phase of COVID-19.

Progression. Follows the natural history of severe COVID-19: an early viral-replication phase (where interferon deficiency is most consequential) transitioning to a late hyperinflammatory phase with hypoxemia and ARDS. Progression can be rapid. The episode is self-limited in the sense of resolving (recovery) or proving fatal, rather than chronic/lifelong — though the predisposition persists for future ssRNA-viral exposures.

Patterns / critical periods. There is a well-defined early therapeutic window: interferon replacement helps when given early but not late (see Treatment). This maps onto the biology — the deficiency matters most during early viral control.

Section 9 — Inheritance and Population

Epidemiology. No standalone prevalence/incidence figure exists because the disease is conditional on a pandemic exposure. Among the exposed with severe disease: deleterious TLR7 variants in 2.1% of severely affected males vs 0% asymptomatic (PMID: 33650967); ~1% of life-threatening COVID-19 in men under 60 is attributable to X-linked TLR7 deficiency (PMID: 34413140).

Inheritance. X-linked recessive, environmentally (SARS-CoV-2) conditioned. Males are hemizygous and affected; females are generally protected.

Penetrance / expressivity. Described as high penetrance for hypoxemic pneumonia upon infection (PMID: 36880831), but penetrance is necessarily conditional on infection and is modulated by viral dose, variant severity (LOF vs hypomorphic), age, and sex. Expressivity is variable (critical pneumonia to milder disease).

Sex ratio. Strongly male-predominant. Mechanistic basis: (1) hemizygosity; (2) escape from X-inactivation — biallelic TLR7 expression in up to 30% of female immune cells buffers heterozygous females (PMID: 38481993); (3) androgens suppress, and female pDCs produce more, IFN-I. In the Spanish cohort, LOF/hypomorphic variants were found only in male cases, with no skewed X-inactivation in female carriers (PMID: 40423910).

Sex-consistency of rare-variant burden. Notably, the population burden association of rare deleterious TLR7 variants with severe disease was statistically consistent across sexes (5.3-fold) (PMID: 36327219) — biallelic females carrying two hits, or heterozygous females with unfavorable expression, can still be at risk, even though clinically ascertained severe cases are overwhelmingly male.

Population demographics. Variants have been identified across Dutch, Italian, and Spanish cohorts and in multinational consortia (12 countries in the burden study). No single founder mutation; most variants are private/family-specific. Carrier frequency of deleterious variants is very low (ultra-rare in gnomAD).

Section 10 — Diagnostics

Genetic testing (definitive). Diagnosis rests on identifying a deleterious TLR7 variant, usually via whole-exome or whole-genome sequencing, as in the founding studies (rapid WES, PMID: 32706371). Targeted TLR7 single-gene sequencing or inclusion of TLR7 in inborn-errors-of-immunity / severe-COVID gene panels is appropriate. Because many variants are private missense, functional validation is essential — luciferase reporter assays and transcriptomic response to TLR7 agonists classify variants as LOF, hypomorphic, or benign (PMID: 40423910, PMID: 34952932).

Functional / immunological assays. Stimulate patient PBMCs or isolated pDCs with TLR7 agonists (imiquimod/R837, R848) and measure IFN-α/IFN-γ and ISG induction (RNA-seq or protein). TLR7-deficient cells show profound impairment (PMID: 34952932). Low pDC IFN-α on TLR7/8 stimulation is a functional biomarker (PMID: 41961811).

Laboratory tests. General severe-COVID labs (lymphopenia, elevated inflammatory markers). Low circulating/inducible type I IFN supports the diagnosis.

Imaging. Chest CT showing bilateral ground-glass opacities/consolidation typical of severe viral pneumonia (supportive, non-specific).

Clinical criteria / differential diagnosis. A young man with no major comorbidity presenting with unexpectedly severe/critical COVID-19 should prompt consideration of IMD74 and related IEIs. Differential: autosomal inborn errors of type I IFN immunity (e.g., IRF7, IFNAR1); MyD88/IRAK-4 deficiency (phenocopy, PMID: 36880831); and the acquired phenocopy, anti–type I IFN autoantibodies (present in ≥10% of critical COVID-19, PMID: 37209324). Autoantibody testing distinguishes the acquired form.

Screening. Genetic screening for TLR7 has been proposed for young men with severe COVID-19 without predisposing comorbidities (PMID: 34367187). Cascade testing of male relatives and carrier evaluation of female relatives is reasonable.

Section 11 — Outcome / Prognosis

Survival / mortality. Prognosis tracks that of critical COVID-19: high morbidity, substantial ICU mortality in the pre-vaccine era, particularly in those progressing to ARDS/ECMO. There is no disease-specific survival curve distinct from severe COVID-19 overall, but affected males are at high risk of life-threatening disease upon infection.

Morbidity and function. During the acute episode: mechanical ventilation, ECMO, prolonged ICU stay. Survivors face post-ICU/post-COVID sequelae. Between infections, carriers are generally healthy.

Disease course / recovery. The episode resolves or is fatal; recovery potential is good for those who survive the acute phase, though the predisposition persists.

Prognostic factors. Earlier antiviral/interferon intervention (favorable), timing within the early window, variant severity (LOF worse than hypomorphic), age, and co-existing anti-IFN autoantibodies (which would compound the deficiency). Prior vaccination is strongly favorable.

Section 12 — Treatment

IMD74 lacks a dedicated approved therapy; management combines standard severe-COVID care with a mechanism-targeted rationale: replace the missing interferon early and remove the viral trigger.

Interferon replacement (mechanism-targeted; the central rationale). Because the defect is failed early IFN production, exogenous interferon is biologically rational. The TOGETHER platform RCT showed a single early subcutaneous dose of pegylated interferon lambda-1a (type III IFN-λ) in outpatients within 7 days of symptom onset reduced hospitalization/ED visits to 2.7% vs 5.6% placebo (RR 0.49; 95% Bayesian CI 0.30–0.76; posterior probability of superiority >99.9%) (PMID: 36780676). Crucially, benefit is time-dependent: a phase 2 trial in already-hospitalized (late) patients was negative (global OR 0.76; 95% CI 0.35–1.66; p = 0.49) (PMID: 40818744), and an early small outpatient trial did not shorten viral shedding (PMID: 33785743). Caveat: these RCTs were in general (genotype-unselected) populations; genotype-stratified trials in TLR7-deficient patients have not been done, so extrapolation is inferential. NCIT: Interferon Therapy; Recombinant Interferon.

Antivirals. Early direct-acting antivirals (e.g., nirmatrelvir/ritonavir, remdesivir, molnupiravir) to limit replication during the window when IFN deficiency is most consequential. NCIT: Antiviral Agent.

Immunomodulation in the inflammatory phase. Standard severe-COVID care (dexamethasone, IL-6 blockade such as tocilizumab, JAK inhibitors) for the late hyperinflammatory phase. Note the biological tension: IFN helps early, anti-inflammatory therapy helps late.

Pharmacogenomic / iatrogenic caution. Propofol directly binds TLR7 and inhibits its association with MyD88, attenuating IFN responses (PMID: 35899460) — a consideration for sedation choice in these patients.

Prevention as treatment adjunct. Vaccination removes/attenuates the obligate trigger and is the single most important intervention (see Section 13).

Advanced / experimental. No gene therapy exists. Conceptually, IFN-based or pDC-targeted strategies and early IFN-λ remain the most rational experimental directions; genotype-guided trials are a logical next step.

Section 13 — Prevention

Primary prevention. Vaccination against SARS-CoV-2 is the cornerstone — it reduces infection and severity and thereby removes the condition under which the genotype becomes pathogenic. Vaccination is associated with reduced inflammatory marker trajectories after infection (PMID: 37659419). Risk-factor modification and exposure avoidance in known carriers.

Secondary prevention. Early diagnosis and early antiviral/IFN intervention in infected carriers (exploiting the early therapeutic window). Prioritization of at-risk males for early testing and treatment.

Genetic screening and counseling. Proposed genetic screening of young men with severe COVID-19 without comorbidity (PMID: 34367187); cascade genetic testing of relatives; genetic counseling for X-linked inheritance (carrier mothers, 50% transmission to sons). Female carriers should be informed that biallelic TLR7 expression generally protects them but that rare-variant risk is statistically sex-consistent.

Tertiary prevention. Prevent complications of severe COVID-19 (standard ICU prophylaxis, early immunomodulation in the inflammatory phase).

Section 14 — Other Species / Natural Disease

Taxonomy / orthologs. TLR7 is evolutionarily conserved. Mouse Tlr7 (NCBI Gene 170743) is the principal ortholog; rat and other mammalian orthologs exist. The receptor's ssRNA-sensing function is conserved across mammals.
Natural disease. No well-documented naturally occurring "IMD74-equivalent" (TLR7-deficiency severe-COVID) disease in companion animals or wildlife is established in the reviewed literature. Cross-species SARS-CoV-2 susceptibility (e.g., in certain mammals) exists but is not characterized as a TLR7-deficiency phenotype.
Comparative biology. The TLR7–MyD88–IFN axis is conserved, making mouse Tlr7 models informative for mechanism. Species differences in TLR7 ligand specificity and endosomal biology temper direct translation.
Zoonotic note. SARS-CoV-2 itself is zoonotic in origin, but IMD74 as a host-genetic condition is human.

Section 15 — Model Organisms

Mouse (Tlr7). Tlr7-knockout mice are the standard model for TLR7 function and recapitulate loss of ssRNA/imiquimod responsiveness and impaired IFN induction. They are widely used to dissect the TLR7→MyD88→IRF7 axis. Relevance to IMD74: strong for the sensing/IFN mechanism; the human COVID phenotype is only partially modeled because murine SARS-CoV-2 infection requires adapted virus or humanized ACE2.
Gain-of-function / lupus models. TLR7 gain-of-function and the downstream SLC15A4–TASL–IRF5 axis drive murine lupus (PMID: 42679023, PMID: 34197340), illuminating the opposite (hyperfunction) end of the TLR7 dosage spectrum and the bidirectional disease relevance of the gene.
In vitro / cellular models. Patient-derived PBMCs and pDCs stimulated with TLR7 agonists (imiquimod, R848), and HEK/reporter cell luciferase assays for variant classification, are the key human in-vitro systems (PMID: 34952932, PMID: 40423910).
Model limitations. Mouse models do not reproduce the full human severe-COVID pneumonia phenotype; human cellular assays capture the sensing/IFN defect but not whole-organism disease. No perfect animal model of IMD74 exists.
Resources: MGI (mouse Tlr7), IMPC/IMSR for knockout lines.

Mechanistic Model / Interpretation

  Hemizygous TLR7 loss-of-function variant (Xp22.2, male host)
        │
        ▼
      Non-functional endosomal TLR7 (dual G/U-ssRNA sensor)
        │  SARS-CoV-2 infection (obligate trigger)
        ▼
   Viral ssRNA NOT sensed in endosome  ◄──── structural basis: 2 ligand sites (PMID 27742543)
        │
        ▼
      No MyD88/IRAK4 signaling  (phenocopied by MyD88/IRAK4 deficiency)
        │
        ▼
   pDCs fail to produce type I/III IFN  (↓IFNA/IFNG/ISGs; PMID 34952932)
        │
  ┌─────────────┴─────────────┐
  ▼ (LOF branch)              ▲ (GOF mirror branch)
  Early antiviral defense fails   Hyperresponsive TLR7 → excess
  │                        early IFN → near-sterilizing
  ▼                        immunity + chilblains (PMID 40227192)
  Unchecked SARS-CoV-2 replication
  │
  ▼
  Late hyperinflammation / macrophage cytokine storm (PMID 36083891)
  │
  ▼
  Hypoxemic COVID-19 pneumonia / ARDS (high penetrance; PMID 36880831)

  THERAPEUTIC LOGIC:  replace IFN EARLY (IFN-λ RCT, PMID 36780676)
      — ineffective if given LATE (PMID 40818744)

The unifying interpretation is TLR7 dosage: too little early interferon (LOF) → severe COVID-19; too much (GOF) → autoinflammation/lupus but viral protection. IMD74 is the LOF pole of this axis. The clinical corollary — intervene early with interferon and remove the trigger by vaccination — follows directly from the causal chain.

Evidence Base

PMID	Title (abbrev.)	Role	Evidence type
32706371	Genetic variants among young men with severe COVID-19	Founding discovery (Dutch families, rapid WES)	Human clinical/genomic
33650967	TLR7 variants in males (GEN-COVID)	Replication: 2.1% of severe males, 0% asymptomatic	Human case-control
34413140	X-linked TLR7 deficiency in ~1% of men <60	Quantifies attributable fraction; ≥10% IFN paradigm	Human cohort
36880831	MyD88/IRAK-4 deficiency & hypoxemic COVID-19	Defines sensor/adaptors/pDC mechanism; high penetrance	Human clinical
34952932	Rare TLR7 variants impair cytokine signaling	Functional/transcriptomic proof of pathway impairment	In vitro / patient cells
38481993	Androgens & biallelic TLR7 expression	Basis for male predominance / carrier protection	Human immunology
40423910	Spanish multicentric TLR7 study	Variant classification (N215S LOF; D332G hypomorphic); no skewed XCI	Human genetic/functional
40227192	TLR7 hyperresponsiveness & chilblains	GOF mirror branch; dosage model	Human mechanism
27742543	TLR7 dual receptor structure	Structural basis for sensing lost in LOF	Structural biology
36780676	Early peginterferon lambda (TOGETHER)	RCT: early IFN reduces progression (RR 0.49)	Human RCT
40818744	Peginterferon λ in hospitalized patients	Negative late-treatment trial (OR 0.76, p=0.49)	Human RCT
36327219	Exome-wide burden (HGI)	5.3-fold risk; sex-consistent	Large human genetic
37209324	Anti–type I IFN auto-Abs in BAL	Acquired phenocopy / differential	Human clinical
36083891	pDC–macrophage cytokine storm	Downstream inflammatory branch	Human/mechanistic

Key verbatim support. - "Severe coronavirus disease 2019 (COVID-19) can occur in younger, predominantly male, patients without preexisting medical conditions." (PMID: 32706371) - "Overall, we found TLR7 deleterious variants in 2.1% of severely affected males and in none of the asymptomatic participants." (PMID: 33650967) - "X-linked recessive deficiency of TLR7, a MyD88- and IRAK-4-dependent endosomal ssRNA sensor, impairs SARS-CoV-2 recognition and type I IFN production in plasmacytoid dendritic cells (pDCs)… underlying hypoxemic COVID-19 pneumonia with high penetrance." (PMID: 36880831) - "Our investigation revealed a profound impairment of the TLR7 pathway in patients carrying loss-of-function variants." (PMID: 34952932) - "TLR7 is a dual receptor for guanosine and uridine-containing ssRNA … all formed an activated m-shaped dimer with two ligand-binding sites." (PMID: 27742543) - "carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75-10.05, p = 5.41x10-7). This association was consistent across sexes." (PMID: 36327219) - "A total of 25 of 931 patients (2.7%) in the interferon group had a primary-outcome event, as compared with 57 of 1018 (5.6%) in the placebo group … relative risk, 0.49." (PMID: 36780676)

Limitations and Knowledge Gaps

Conditional penetrance is hard to quantify. Because disease requires SARS-CoV-2 infection, true penetrance depends on exposure, viral dose, and timing; "high penetrance" is an estimate conditional on infection, not an unconditional figure.
No genotype-stratified trials. All interferon RCT evidence comes from genotype-unselected populations. Whether early IFN-λ specifically rescues TLR7-deficient patients has not been tested directly — the therapeutic rationale is strong but inferential.
Variant interpretation burden. Many TLR7 variants are private missense requiring functional validation; VUS abound, and standardized ACMG classification for this conditional phenotype is still maturing.
Female risk is paradoxical. Clinically ascertained cases are overwhelmingly male, yet the population burden is sex-consistent (5.3-fold). The quantitative risk to heterozygous and biallelic females is incompletely resolved.
No faithful animal model of the whole-organism severe-COVID phenotype exists; mouse Tlr7 KO captures the sensing defect but not human SARS-CoV-2 pneumonia without humanization.
Overlap with acquired phenocopy. Anti–type I IFN autoantibodies produce an overlapping end phenotype; disentangling genetic from acquired IFN deficiency in individual patients requires both genetic and autoantibody testing.
Epidemiology is pandemic-dependent. Prevalence/incidence of the clinical phenotype will vary with viral variants, population immunity, and vaccination coverage.

Proposed Follow-up Experiments / Actions

Genotype-stratified interferon trial. Conduct a prospective early-treatment trial of IFN-λ (or IFN-α) in genetically confirmed TLR7-deficient (and MyD88/IRAK4-deficient) patients at diagnosis, testing the central mechanistic prediction directly.
Prospective screening protocol. Implement rapid TLR7 sequencing plus a functional pDC IFN assay for young men hospitalized with unexplained severe COVID-19, enabling early mechanism-guided therapy and cascade testing.
Standardized functional classifier. Build a validated luciferase + transcriptomic pipeline and a curated variant database to resolve TLR7 VUS and generate ACMG-compatible, functional-evidence-weighted classifications.
Female carrier risk study. Quantify risk in heterozygous and biallelic female carriers as a function of X-inactivation pattern and TLR7 expression, reconciling the sex-consistent burden with male clinical predominance.
Dosage-axis mapping. Systematically map TLR7 LOF↔GOF variants against clinical outcomes (severe COVID-19 vs protection/chilblains vs lupus) to formalize the dosage model and identify the protective "sweet spot."
Avoid TLR7-inhibiting sedation. Evaluate clinically whether propofol (a TLR7 inhibitor) worsens outcomes in TLR7-deficient ventilated patients and whether alternative sedation improves IFN responses.
Broaden the viral scope. Test whether TLR7-deficient individuals are predisposed to severe disease from other ssRNA viruses (influenza, other coronaviruses), which the mechanism predicts.

Report compiled from 5 iterations, 8 confirmed findings, and 31 reviewed papers. Evidence spans human clinical/genomic studies, large population genetics, functional in-vitro assays, structural biology, and randomized controlled trials.

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Diagnosis

Prevalence

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Immunodeficiency 74, COVID-19-Related, X-Linked (IMD74): Comprehensive Disease Characterization Report

Summary

Section 1 — Disease Information

Section 2 — Etiology

Section 3 — Phenotypes

Section 4 — Genetic / Molecular Information

Section 5 — Environmental Information

Section 6 — Mechanism / Pathophysiology

Ordered causal chain

Detail by category

Section 7 — Anatomical Structures Affected

Section 8 — Temporal Development

Section 9 — Inheritance and Population

Section 10 — Diagnostics

Section 11 — Outcome / Prognosis

Section 12 — Treatment

Section 13 — Prevention

Section 14 — Other Species / Natural Disease

Section 15 — Model Organisms

Mechanistic Model / Interpretation

Evidence Base

Limitations and Knowledge Gaps

Proposed Follow-up Experiments / Actions

Artifacts